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ABSTRACT 
 
New methodologies for in vitro analysis of binding 
and functional activity of sigma receptor ligands 
 
JAMES A FISHBACK 
 
Sigma receptors represent a promising drug development target for a number of therapeutic indications 
including cancer, depression, psychostimulant abuse and stroke. To date, two subtypes of sigma receptors 
have been identified; σ1 and σ2. Their respective roles in normal physiology and in disease processes are 
a subject of ongoing studies. Consequently, the discovery and development of subtype specific agonist 
and antagonist ligands remains a key research goal. To date, no in vitro functional assay suitable for 
routine screening of putative sigma ligands has been reported. As a result, radioligand binding assays are 
used as a primary screen. Therefore, to support the critical role of receptor binding assays, a new σ1 
selective radioligand, [
3
H]-SN56, was characterized, and efforts were undertaken to develop medium 
throughput methods for binding affinity determinations for both sigma receptor subtypes. To fill the 
unmet need for an in vitro functional assay for σ1 ligands, preliminary studies were performed to develop 
an immunological assay based on the ligand sensitive interaction of σ1 and binding immunoglobulin 
protein (BiP). The results of the studies with [
3
H]SN56 show that it possesses high affinity and selectivity 
for σ1 receptors and offers considerable advantages over the currently used radioligand, [
3
H](+)-
pentazocine. Competition binding studies with established sigma ligands assayed in rat brain 




H](+)-pentazocine yielded comparable Ki values, indicating that 





H](+)-pentazocine, further supporting the notion that both ligands bind specifically to the site identified 
as the σ1 receptor. Conventional radioligand binding studies for sigma receptors utilize a “cell harvester.” 
Newer medium and high throughput technologies exist that have been applied to the analysis of numerous 
classical receptors. 96-well filtration and scintillation proximity assay (SPA) were evaluated for the 
analysis of sigma receptor ligand binding. Adaptation of the conventional binding assay to the higher 
throughput methods required the use of rat liver membranes because sigma receptor densities were too 
low in rat brain membranes to support reliable filtration in the 96-well format or use with SPA. Analysis 
of a series of reference compounds by 96-well filtration yielded binding affinities that correlated with 
values measured using the conventional method, for both sigma receptor subtypes. Following validation 
with the reference compounds, the 96-well filtration procedure was successfully used to determine Ki 
values for sigma receptors for a novel series of 2(3)-benzothiazolones. Studies with SPA demonstrated 
that this technique also yields results that are equivalent to the conventional method, but the cost of beads 
is prohibitively high with currently available radioligands used in conjunction with tissue derived 
membranes; this cost could potentially be significantly reduced if higher specific activity radioligands 
were available or if membranes from cells overexpressing sigma receptors were utilized. Preliminary 
studies were performed to assess the feasibility of developing a high throughput in vitro functional assay 
for the σ1 receptor using Alphascreen as a read-out of agonist induced disruption of the σ1/BiP complex. 
These efforts, which included a basic assessment of the Alphascreen platform, and attempts to determine 
if endogenous or recombinant proteins could serve as suitable substrates, were largely unsuccessful. 
However, these experiments did yield information that should prove useful for future development of an 
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1.1. Sigma receptors 
The sigma receptor was first described as a subtype of opioid receptors based on behavioral 
observations in dogs following administration of the benzomorphan, N-allylnormetazocine 
(SKF10,047) [1]. Subsequent in vitro observations indicated that this binding site represented a 
new class of non-opioid receptor [2, 3]. Sigma receptors are widely distributed in the body with 
significant concentrations in most major organs, including the brain, heart, liver, kidney and 
spleen [4-8]. In the brain, they are found predominantly in structures associated with limbic and 
endocrine function, including the hippocampus, frontal cortex, hypothalamus, and olfactory bulb 
[9, 10].  
 
Two subtypes of sigma receptors, σ1 and σ2, have been identified based on differences in 
pharmacological profile, tissue distribution, and molecular characterization [6, 11-15]. Their 
respective roles in normal physiology and in disease processes are a subject of ongoing 
pharmacological studies. The successful cloning, recent advances in the understanding of the 
functional role of σ1 at the molecular level, and the availability of σ1 subtype specific ligands 
provide some of the necessary tools for rational therapeutic targeting of this ubiquitous protein. 
However, existing knowledge of σ2 is more limited, rendering specific targeting of this subtype 
problematic.  
 
The σ1 receptor is a highly conserved 223 amino acid protein that has been cloned from several 
species, including rodents and humans [16-20]. Functionally, σ1 receptors appear to operate 
primarily via protein-protein interactions and have been shown to modulate the activity of 
various ion channels and signaling molecules [21]. σ1 receptors are expressed on the 
endoplasmic reticulum (ER) and can translocate between different cellular compartments in 
response to ligand binding [22-24]. Accordingly, the discrete activities that are ascribed to the σ1 
receptor depend on its cellular location. σ1 mediated modulation of ion channels on the 
plasmalemma [25-30] and control of intracellular calcium via interactions with inositol 
trisphosphate (IP3) receptors on the ER are well documented [31-35]. The endogenous ligand(s) 
for σ1 have yet to be conclusively identified; however, a number of candidates have been 
proposed, including some neuroactive steroids, sphingolipids, and most recently N,N-
dimethyltryptamine [36-38].  
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Considerably less is known about the σ2 receptor because selective ligands for this subtype have 
not been available, and attempts to isolate the protein have been unsuccessful [39, 40].  Efforts 
over the last decade to develop σ2 specific ligands have met with some success, enabling more 
concise determinations of σ2 specific effects [41-43]. Sigma receptors, particularly σ2 are 
overexpressed in cancer cells and σ2 agonists can inhibit their proliferation and induce apoptotic 
cell death by altering cytosolic Ca
2+
, ceramide and sphingolipid levels [42, 44, 45]. Because σ2 
receptors are overexpressed in cancer cells they can function as endogenous markers for 
proliferating tumors. Consequently, considerable effort has been expended in developing σ2 
specific radioprobes for SPECT (single-photon emission computed tomography) and PET 
(positron emission tomography) imaging [46-49]. 
 
1.2. Utility of radioligands and radioligand binding methods in sigma receptor research 
Application of in vitro binding studies with sigma receptor specific radioligands has resulted in: 
1) identification of sigma receptors as unique non-opioid receptors [2, 3], 2) identification of two 
sigma receptor subtypes, σ1 and σ2 [12-14], 3) delineation of their anatomical distributions [4, 
50-52], and 4) determination of binding affinities of novel compounds. More recent reports show 
significant interest in the development of sigma subtype specific radioligands for PET and 
SPECT imaging [46-49, 53-56]. These imaging agents may prove useful in: 1) mapping sigma 
receptors in the human brain, 2) the diagnosis of cancer [48, 53, 56], Alzheimer’s and 
Parkinson’s disease [55], and 3) in the evaluation of antidepressant therapeutics [54]. 
 
1.3. σ1 selective radioligands 
DeCosta et al. [57] first described [
3
H](+)-pentazocine, a highly selective radioprobe for σ1 
receptors. Subsequent studies demonstrated that [
3
H](+)-pentazocine labeled a single class of 
sites in guinea-pig brain that correlated with the profile observed following labeling with the 
prototypic sigma probe [
3
H](+)-3-PPP ((+)-3-(3-hydroxyphenyl)-N-(1-propyl)-piperidine) [58]. 
[
3
H](+)-Pentazocine exhibits low levels of non-specific binding and high affinity for σ1 receptors 
(Kd = 4.8 ± 0.4 nM), with an over 700-fold preference for the σ1 over the σ2 subtype [58]. Since 
the introduction of [
3
H](+)-pentazocine, no alternative has been introduced that demonstrates 
superior σ1 selectivity and specificity. A number of new radioligands have been proposed, but 





piperazine) demonstrates moderate affinity for 5-HT2B receptors (IC50 = 190 nM), while 
[
3
H]SA4503 (1-(3,4-dimethoxyphenethyl)-4-(3-phenylprophyl) piperazine) lacks subtype 




pyrrolidinone L-tartrate) displays slow association kinetics, which renders its routine use 
impractical [59-62]. In recent years, the availability and quality of commercially available 
[
3
H](+)-pentazocine has become unreliable, creating some urgency for the development of an 
acceptable alternative radioligand for σ1 receptors. [
3
H](+)-Pentazocine also demonstrates 




H]SN56, and novel analogues of SN56 
SN56 (3-(2-(azepan-1-yl)ethyl)-6-propylbenzo[d]thiazol-2(3H)-one) was recently identified as a 
highly selective and subtype-specific ligand with subnanomolar affinity for 1 receptors [63]. 
Because of its high affinity and unique selectivity profile, SN56 was chosen for evaluation as a 
tritiated radioligand for use in competition binding assays. Additionally, a series of analogues of 
SN56 were synthesized by collaborators (Rohit Bhat in the lab of Dr. Christopher McCurdy, 
University of Mississippi, University, MS) to further delineate relationships between structure 
and binding affinity among this class of compounds. Three general themes were explored in this 
benzothiazolone series which include variations in: 1) the size of the attached heterocycle, 2) the 
heterocycle linker chain length, and 3) the composition of the alkyl or acyl chain at position 6 of 
the benzothiazolone system. This series of compounds were analyzed as part of this dissertation 
using the medium throughput 96-well filtration binding method described in this document. 
 
1.5. Medium and high throughput binding methods 
Instrumentation and materials have been developed for higher throughput receptor binding 
analyses employing filtration and scintillation proximity assays (SPA) in 96-well formats. These 
assays are in widespread use in binding experiments with membrane bound receptors (e.g. 
serotonin, opioid, somatostatin, acetylcholine) derived from tissue, and cultured cell-derived 
membranes [64-68]. In addition to increasing throughput, these assay technologies have the 
potential to improve assay accuracy and precision, and reduce costs relative to conventional 
filtration based assays [68-73]. Filtration assays in the 96-well format are operationally 
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equivalent to conventional filtration assays except that reduced sample sizes are utilized and 96-
well specific cell harvesters and scintillation counters that can accommodate the 96-well format 
are employed for sample processing. Scintillation proximity assays (SPA) utilize scintillant 
containing microscopic beads which produce photons when radiolabeled molecules are in close 
proximity to the bead surface [70, 74]. Cell membranes associate with the beads via interactions 
between wheat germ agglutinin bound to the bead surface and cell membrane glycosylation sites 
[70, 74]. Binding of radioligands to receptors present in the membranes and associated with the 
treated bead surface give rise to a signal commensurate with the amount of bound radioligand 
[70, 74]. Published reports of the use of 96-well filtration in the analysis of sigma receptor 
binding are limited to two research groups, the Mach group from Washington University [75-78] 
and the Wünsch group from the University of Münster [79, 80]; therefore, it is apparent that the 
technique is not in widespread use in the sigma receptor field. To date no reports of the use of 
SPA in the analysis of sigma receptor ligands have been published in the literature. 
 
1.6. Binding of sigma ligands in mammalian liver versus brain derived isolates 
Development of higher throughput methods for analysis of binding of sigma receptors requires 
higher densities of sigma receptors than are expressed in rat or guinea-pig brain P2 membranes. 
Several researchers have reported high densities of both sigma receptor subtypes in guinea-pig 
and rat liver tissues [6, 16, 52]. Representative Bmax values determined for σ1 and σ2 in rat brain 
P2 are ~300-500 fmol/mg and ~1000 fmol/mg, respectively [81, 82], while representative Bmax 
values determined for σ1 and σ2 in rat liver P2 are approximately 3 pmol/mg and 9 pmol/mg, 
respectively [6]. The six to ten-fold higher density of σ1 receptors in rat liver, relative to rat 
brain, is expected to facilitate the use of high throughput radioligand binding methods with the 
constraints imposed by conditions required to prevent radioligand depletion and sample size 
limitations imposed by the higher throughput formats. Reports on rigorous direct comparisons of 
binding of σ1 ligands in isolates from rat brain versus rat liver labeled with [
3
H](+)-pentazocine 
support the pharmacological equivalency of receptors derived from the two tissues [16, 59, 83]. 
Most contemporary binding studies for σ2 already employ rat liver P2 membranes so no change 








 and ligand sensitive interaction of σ1 with binding immunoglobulin 
Binding immunoglobulin protein (BiP/GRP78) is a Ca
2+
 binding ER chaperone that functions  as 
an ER Ca
2+
 buffer, modulates the unfolded protein response (UPR), and aids in protein folding 
[89, 90]. In 2007 Hayashi and Su [91] reported that the interaction of σ1 with BiP regulates Ca
2+
 
signaling between the ER and mitochondria via IP3 receptors localized at focal points called the 
mitochondrial associated membrane (MAM). Evidence for a σ1/BiP complex was obtained from 
wild-type CHO (Chinese hamster ovary) cells by co-immunoprecipitation of a σ1/BiP complex 
using anti-bodies for either protein [91]. This complex was found with or without chemical 
crosslinking prior to cell lysis, suggesting that the interaction occurs endogenously and is not an 
isolation artifact [91]. The sensitivity of the σ1/BiP protein complex to sigma agonists and Ca
2+
 
was unequivocally demonstrated in isolates from CHO cells expressing σ1-EYFP (enhanced 
yellow fluorescent protein) [91]. Co-immunoprecipitation studies with crude cell lysates from 
CHO cells expressing σ1-EYFP exposed in situ to σ1 agonists, showed a dose-dependent 
decrease in co-precipitated BiP protein following immunoprecipitation with an anti-EYFP linked 
sepharose affinity matrix [91]. Application of 1 antagonists in this system prevented the action 
of agonists but had little effect or slightly promoted formation of the complex when they were 
administered alone [91]. 
 
1.8. Alphascreen technology 
Alphascreen is a well developed assay technology marketed by Perkin Elmer (Waltham, MA) 
with proven applications in the detection of low to high affinity protein interactions in samples of 
purified recombinant, membrane bound, and solubilized proteins from cells and tissues [92, 93]. 
The basis for the Alphascreen is the generation of a luminescent signal when the “donor” and 
“acceptor” beads are brought into close proximity by association of proteins captured on the 
respective beads [92, 93]. This general property can be exploited in both signal increasing and 
signal decreasing assays, which are well represented by kits available from Perkin Elmer for 
assaying interactions as diverse as receptor/ligand interactions, kinase and protease assays and 
ELISA-type immunoassays [92, 93]. A recently described assay of inhibitors of the interaction of 
heat shock protein 90 (Hsp90) and its co-chaperone, heat shock organizing protein (HOP), 
demonstrates the successful application of this technology in the analysis of small molecule 
inhibitors of a protein-protein interaction [94, 95]. Some advantages of the Alphascreen 
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technology include, 1) numerous available bead chemistries, permitting the detection of diverse 
protein interactions with flexible assay design options, 2) high sensitivity with low signal to 
background ratio, and 3) adaptability to miniaturization and high throughput screening (HTS). 
 
1.9. Applications for high throughput methods in sigma receptor research 
In addition to routine analysis of putative novel sigma ligands, high throughput binding and 
functional assays for σ1 receptors may be suitable for screening compound libraries such as the 
Prestwick Chemical Library (Washington, DC), a library composed of 1200 FDA-approved 
(U.S. Food and Drug Administration) small molecule drugs with high chemical and 
pharmacological diversity. The results could identify new compounds, or structural or 
pharmacological classes of compounds whose therapeutic activity may be due, in part, to 
interaction with σ1 receptors. Antidepressants are an example of a druggable pharmacological 
class with varying chemical structures that demonstrate affinity for the sigma receptor [96]. The 
availability of a medium or high throughput functional assay would also facilitate tests for 
correlation between binding affinity and functional activity for these and other classes of current 
and future therapeutics. 
 
1.10 Summary 
Radioligand binding approaches remain an essential component for the discovery and 
development of novel sigma receptor ligands that have potential use as therapeutics and as 
imaging probes. New novel radiolabeled probes and advances in high throughput radioligand 
binding technologies provide an opportunity to significantly improve performance standards for 
this critical phase of drug discovery. The successful development of an in vitro functional assay 
for the σ1 receptor would bring a powerful analytical tool that is not currently available to sigma 
receptor research. New capabilities enjoyed as a result of these efforts are anticipated to aid in 
the discovery and design of future drug development candidates as well as provide further insight 






1.11 Research objectives 
The objective of these studies was to develop new in vitro tools to examine the binding and 
functional activity of sigma ligands by addressing the following specific aims: 
 
Aim I  
Demonstrate the suitability of [
3
H]SN56 for use in conventional radioligand binding assays. 
 
Aim II  
Develop medium throughput assays for the determination of binding affinities of novel σ ligands. 
 
Aim III  
Perform preliminary studies to support the development of a high throughput in vitro functional 
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2.1 Abstract  
 
The study of the binding characteristics of σ ligands in vivo and in vitro requires radiolabeled 
probes with high affinity and selectivity. The radioligand presently used for in vitro studies of the 
σ1 receptor, [
3
H](+)-pentazocine, has significant limitations: it is difficult to synthesize, has 
limited chemical stability, and can be problematic to obtain. Evaluation of a series of novel 
2(3H)-benzothiazolone compounds revealed SN56 to have subnanomolar and preferential 
affinity for the σ1 subtype, relative to σ2 and non-sigma, binding sites. The goal of this study 
was to characterize the binding of [
3
H]SN56 to σ1 receptors isolated from rat brain. Standard in 
vitro binding techniques were utilized to 1) determine the specificity and affinity of binding to 
σ1 receptors, 2) confirm that [
3
H]SN56 labels sites previously identified as σ1 by comparing 
binding to sites labeled by [
3
H](+)-pentazocine, and 3) characterize the kinetics of binding. The 
results indicate that [
3
H]SN56 exhibits 1) specific, saturable, and reversible binding to the σ1 
receptor, with Bmax = 340 ± 10 fmol/mg and Kd = 0.069 ± 0.007 nM, 2) competitive 
displacement by classical sigma compounds, yielding σ1 Ki values consistent with those reported 
in the literature, and 3) binding kinetics compatible with a 90 min incubation, and filtration for 
separation of free and bound radioligand. The results of these studies suggest that [
3
H]SN56 may 
serve as a viable alternative to [
3







The sigma receptor was first identified as an opioid receptor subtype based on behavioral studies 
of morphine-like drugs in dogs [1]. Subsequent in vitro binding data revealed that this site 
represents a new class of non-opioid receptor [2]. To date, two subtypes of sigma receptors (σ1 
and σ2) have been identified based on differences in ligand selectivity, tissue distribution, and 
molecular characterization [3]. The σ1 receptor has been cloned from multiple species [4-9] and 
a significant number of ligands with high affinity and selectivity for it are available. The σ2 
receptor is less well characterized; it has not been cloned, and few specific ligands have been 
described.  
 
The σ1 receptor is involved in numerous physiological processes and disease states, and in vivo 
and in vitro studies indicate that modulation of σ1 receptors using sigma specific ligands can 
affect these systems [10-13]. Consequently, the σ1 receptor is recognized as a potential 
medication development target and efforts to identify novel selective compounds are ongoing. 
While the σ2 receptor may also represent a feasible drug development target, further research in 
this area will require the discovery of additional selective ligands for this subtype. The focus of 
the current work is therefore limited to the characterization of σ1 binding.   
 
DeCosta et al. [14] first described [
3
H](+)-pentazocine, a highly selective radioprobe for σ1 
receptors. Subsequent studies demonstrated that [
3
H](+)-pentazocine labeled a single class of 
sites in guinea-pig brain that correlated with the profile observed following labeling with the 
prototypic σ1 probe [
3
H](+)-3-PPP ((+)-3-(3-Hydroxyphenyl)-N-(1-propyl)-piperidine) [15]. 
[
3
H](+)-Pentazocine exhibited low levels of non-specific binding and high affinity for σ1 
receptors (Kd = 4.8 ± 0.4 nM), with >700-fold preference for the σ1 over the σ2 subtype [15]. 
[
3
H](+)-Pentazocine does, however, exhibit shortcomings, including poor chemical stability, 
which limits its usefulness in routine studies.  
 
Efforts to design new σ1 specific ligands have produced a limited number of radioprobes useful 
for exploring the pharmacology of the σ1 receptor. Unfortunately, like [
3
H](+)-pentazocine, each 
of the proposed new radioprobes exhibits limitations, such as slow association kinetics, marginal 
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sigma subtype selectivity, or nanomolar affinity for other receptors. Therefore, we sought to 
characterize the performance of SN56 (3-(2-(azepan-1-yl)ethyl)-6-propylbenzo[d]thiazol-2(3H)-
one), a novel σ1 selective, 2(3H)-benzothiazolone compound, as a tritiated radioligand, for use in 
σ1 competition binding experiments. SN56 exhibited sub-nanomolar affinity (Ki σ1 = 0.56 nM) 
and >1,000 fold selectivity for the σ1 subtype relative to the σ2 subtype in guinea-pig brain 
membranes, and at least 350-fold greater affinity for the σ1 receptor versus a battery of receptors 
and transporters [16]. These binding characteristics coupled with a simple and economical 
synthetic scheme suggested [
3
H]SN56 may provide a viable alternative to [
3
H](+)-pentazocine in 
competition binding studies of the σ1 receptor.   
 
2.3 Materials and Methods 
 
2.3.1 Reagents and chemicals 
Reagents and starting materials for the synthesis of SN56 were obtained from commercial 
suppliers and were used without purification. Pre-coated silica gel GF Uniplates from Analtech 
(Newark, DE) were used for thin-layer chromatography (TLC). Column chromatography was 
performed on silica gel 60 (Sorbent Technologies, Atlanta, GA). 1H and 13C NMR spectra were 
obtained on a Bruker APX400 (Billerica, MA) at 400 and 100 MHz, respectively. High 
resolution mass spectra (HRMS) were recorded on a Waters Micromass Q-Tof Micro mass 
spectrometer with a lock spray source (Milford, MA). Mass spectra (MS) were recorded on a 
WATERS ACQUITY Ultra Performance LC (Milford, MA) with ZQ detector in ESI mode. 
Elemental analysis (C, H, N) was performed on a Perkin-Elmer CHN/SO Series II Analyzer 
(Waltham, MA). Chemical names were generated using ChemDraw Ultra (CambridgeSoft, 
version 10.0, Cambridge, MA). [
3
H](+)-Pentazocine (29 Ci/mmol) was purchased from Perkin 
Elmer (Boston, MS). (+)-SKF10,047 ((−)-N-allylnormetazocine hydrochloride), (+)-pentazocine, 
(-)-pentazocine, haloperidol, 1,3-di-o-tolylguanidine (DTG), bovine serum albumin (BSA) 
fraction V, sucrose, NaCl, tris(hydroxymethyl)aminomethane (Tris), 1N hydrochloric acid 
solution, and glacial acetic acid were purchased from Sigma-Aldrich (St. Louis, MO). Coomassie 
Protein Assay reagent, Ecoscint scintillation fluid and Brandel GF/B filter papers, 2.25 x 12.25 




2.3.2 Synthesis of [
3
H]SN56  
The design strategy for generating [
3
H]SN56 involved replacing a bromine atom on the aromatic 
ring of SN56 with a tritium atom (Figure 1). The precursor compounds for the synthesis of 
[
3
H]SN56, compounds 1, 2, 3 and 4 were synthesized by Christophe Mesangeau in the laboratory 
of Christopher McCurdy at the University of Mississippi. The preparation of the brominated 
precursor 4 is described below. Compounds 1 and 2 were prepared according to previously 
described procedures with minor modifications [17, 18]. Selective bromination of the 6-
propylbenzo[d]thiazol-2(3H)-one 2 at the C-4 position was effected with bromine in acetic acid 
at room temperature (RT). The bromo derivative was alkylated with 2-
(hexamethyleneimino)ethylchloride in the presence of potassium carbonate in 
dimethylformamide (DMF) to yield 4. Compound 4 was radiolabeled with tritium (30 Ci/mmol) 
by AmBios Labs, Inc. (Newington, CT). 
 
2.3.3 6-Propionylbenzo[d]thiazol-2(3H)-one (1)  
Dimethylformamide (5.96 ml, 76.73 mmol) was added slowly to aluminum chloride (35.5 g, 
264.6 mmol) with vigorous stirring. After 15 min, 2-hydroxybenzothiazole (5.4 g, 40 mmol) was 
added and the mixture was heated to 45 C. After 15 min, propionyl chloride (3.46 ml, 39.7 
mmol) was added and the reaction mixture was heated to 85 C for 3 h. The hot mixture was 
then poured on ice; the crude product was collected by filtration, and washed with water. The 
solid was dissolved in ethyl acetate and the solvent was washed with water and brine, dried and 
evaporated. The residue was recrystallized from toluene/dioxane (2/1) to give 2.96 g (54%) of 6-
propionylbenzo[d]thiazol-2(3H)-one as a white solid. 1H NMR (DMSO-d6):   12.23 (br s, 1H), 
8.20 (s, 1H), 7.87 (d, J = 8.4 Hz, 1H), 7.17 (d, J = 8.3 Hz, 1H), 2.97 (q, J = 7.1 Hz, 2H), 1.06 (t, J 
= 7.1 Hz, 3H). 13C NMR (DMSO-d6):  198.64, 170.46, 140.13, 131.21, 126.74, 123.69, 
123.04, 111.17, 30.93, 8.22. MS (ESI) m/z 206 (M+-1). 
 
 2.3.4 6-Propylbenzo[d]thiazol-2(3H)-one (2) 
Triethylsilane (4.75 ml, 29.75 mmol) was added to a stirred solution of 1 (2.5 g, 12.06 mmol) in 
trifluoroacetic acid (13 ml). The mixture was stirred vigorously for 2 h at RT. The trifluoroacetic 
acid was removed by evaporation and the residue was purified by chromatography on a silica gel 
column using petroleum ether/ethyl acetate (9:1) as the eluent to give 2.06 g (88%) of 6-
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propylbenzo[d]thiazol-2(3H)-one as a white solid. 1H NMR (DMSO-d6):   11.76 (br s, 1H), 
7.33 (s, 1H), 7.05 (d, J = 8.1 Hz, 1H), 6.99 (d, J = 8.1 Hz, 1H), 2.50 (t, J = 7.4 Hz, 2H), 1.56-1.50 
(m, 2H), 0.84 (t, J = 7.3 Hz, 3H). 13C NMR (DMSO-d6):  169.99, 136.68, 134.23, 126.57, 
123.24, 122.12, 111.22, 36.87, 24.30, 13.54. MS (ESI) m/z 194 (M++1). 
 
2.3.5 4-Bromo-6-propylbenzo[d]thiazol-2(3H)-one (3) 
Bromine (0.45 ml, 8.75 mmol) was added slowly to a solution of 2 (1.5 g, 7.76 mmol) in acetic 
acid (10 ml). The mixture was stirred 15 h at RT, poured into water and extracted with ethyl 
acetate (3  30 ml). The combined organic layers were washed with a 10% solution of potassium 
carbonate followed by brine. The solution was dried over sodium sulfate and evaporated under 
vacuum. The residue was purified by chromatography on a silica gel column using petroleum 
ether/ethyl acetate (9:1) as the eluent to give 0.5 g (24%) of 4-bromo-6-propylbenzo[d]thiazol-
2(3H)-one as a white solid. 1H NMR (CDCl3):   9.29 (s, 1H), 7.26 (s, 1H), 7.12 (s, 1H), 2.56 (t, 
J = 7.6 Hz, 2H), 1.62 (m, 2H), 0.93  (t, J = 7.2 Hz, 2H). 13C NMR (CDCl3):  170.45, 139.35, 
132.22, 129.34, 124.44, 121.24, 103.90, 37.37, 24.48, 13.54. MS (ESI) m/z 270 (M+-1), 272 
(M++1). 
 
2.3.6 3-(2-(Azepan-1-yl)ethyl)-4-bromo-6-propylbenzo[d]thiazol-2(3H)-one hydrochloride (4) 
NaHCO3 (0.51 g, 6.09 mmol) and 2-(hexamethyleneimino)ethylchloride hydrochloride (0.80 g, 
4.06 mmol) were added, with mechanical stirring, to a solution of 3 (0.55 g, 2.03 mmol) in 
anhydrous DMF (15 ml). The reaction mixture was heated to 80 C for 1 h. After cooling, the 
mixture was poured into 80 ml of water, extracted with ethyl acetate (3  60 ml), and the 
combined organic layers were washed with brine and dried. The solvent was removed in vacuo, 
and the residue was chromatographed on a silica gel column using ethyl acetate/petroleum ether 
(4:6) as the eluent. 3-(2-(Azepan-1-yl)ethyl)-4-bromo-6-propylbenzo[d]thiazol-2(3H)-one was 
isolated as a hydrochloride salt (white solid, 0.44 g, 49%) by addition of HCl/dioxane. 1H NMR 
(DMSO-d6):   10.81 (br s, 1H), 7.60 (s, 1H), 7.46 (s, 1H), 4.72 (t, J = 7.2 Hz, 2H), 3.47-3.24 
(m, 6H),  2.56 (t, J = 7.5 Hz, 2H), 1.86 (br s, 4H), 1.67-1.55 (m, 6H), 0.88 (t, J = 7.2 Hz, 3H). 
13C NMR (DMSO-d6):  170.54, 138.87, 132.87, 132.63, 125.62, 121.79, 103.79, 56.73, 55.89, 
43.14, 37.04, 28.58, 27.22, 24.51, 13.81. Analysis calculated for C18H26 BrClN2OS: C, 49.83; 
H, 6.04; N, 6.46. Found: C, 50.06; H, 5.93; N, 6.47. HRMS calculated for C18H26N2OSBr 
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[M+H]+ 397.0949, found 397.0945. A synopsis of the synthetic route of the synthesis of the 
brominated [
3
H]-SN56 precursor is provided in Figure 2. 
 
2.3.7 Membrane preparation 
Crude P2 rat brain homogenates were prepared from male, Sprague Dawley rats (150-200 g) 
purchased from Harlan (Indianapolis, IN) as described previously [19]. All procedures involving 
live animals were performed as approved by the Institutional Animal Care and Use Committee at 
the locations where the assays were performed. Briefly, unanesthetized rats were sacrificed by 
decapitation; brains minus cerebellum were harvested and maintained in ice cold 10 mM 
Tris/0.9% NaCl until processed. Tissues were homogenized with a Potter-Elvehjem homogenizer 
(5-10 strokes with motor driven Teflon pestle) in ice-cold 10 mM Tris-sucrose buffer (0.32 M 
sucrose in 10 mM Tris, pH 7.4) using 10 ml buffer per g of tissue x ~3 g tissue/batch. 
Homogenates from multiple batches were combined and centrifuged for 10 min at 1,000 x g, at 4 
°C. Supernatants were decanted, combined and centrifuged for 15 min at 31,000 x g, at 4 °C. The 
material from centrifugation at 31,000 x g was washed as follows: 1) pellets were re-suspended 
in 10 mM Tris, pH 7.4 using 3 ml buffer per gram of tissue, 2) the resulting suspension was 
incubated for 30 min at 25 °C, 3) the resulting suspension was centrifuged for 15 min at 31,000 x 
g, at 4 °C. The resulting pellets were re-suspended in Tris, pH 7.4 buffer at a final concentration 
of 1 g of tissue per 1.53 ml buffer. Tissue preparations were aliquoted in 1 ml portions and stored 
at -80 °C. The Bradford assay was used to quantitate protein concentration [20]. 
 
2.3.8 Radioligand binding assays 
Initial optimization of assay conditions was performed to maximize total binding and minimize 
non-specific binding. Parameters examined included evaluation of the buffer composition and 
pH, ratio of radioligand to membrane concentration, and determination of ligand and ligand 
concentration for defining non-specific binding. The following optimized conditions were used 
for subsequent studies reported below: 0.5 ml final sample volume, 90 min sample incubation at 
25 ºC, Tris, pH 8.0 (assay buffer), and 100 µM haloperidol (to define non-specific binding). 
Assay termination was effected by vacuum filtration through glass fiber filters on a 24 position 
Brandel cell harvester. Prior to use, filters were presoaked for 30 min in 0.5% polyethyleneimine 
to reduce non-specific binding. Following the initial filtration step, filters were washed 3 times 
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with 5 ml ice-cold 10 mM Tris, pH 8. The conditions determined from the preliminary studies 
were consistent with those reported in the literature for the analysis of σ1 receptor binding using 
[
3
H](+)-pentazocine [15, 21, 22]. It should be noted that it was necessary to prepare [
3
H]SN56 
spiking solutions in 1 mM HCl, to prevent non-specific binding of the radioligand to glass and 
plasticware, which was problematic with solutions prepared in the assay buffer. This requirement 
is not unprecedented and the small amount of acid has no impact on the final pH of the assay 
sample [23].  
 
2.3.9 Association and dissociation assays 
Association and dissociation studies were conducted to confirm that the binding kinetics of 
[
3
H]SN56 were appropriate for a 1-2 h incubation and processing by filtration. Kinetic studies 
were performed with 0.8 nM [
3
H]SN56 and 100 µg membrane. For determination of association 
rates, samples were incubated for times ranging from 5 min to 2 h prior to filtration. For 
determination of dissociation rates, membranes were incubated for 120 min with [
3
H]SN56 prior 
to the addition of 100 µM (final concentration) haloperidol, followed by filtration at times 
ranging from 30 min to 4 h from the addition of haloperidol. The assays were performed in 
duplicate and repeated three times. 
 
2.3.10 Saturation binding assays 
For the determination of Kd and Bmax by saturation binding, ten concentrations ranging from 0.01 
to 0.8 nM of [
3
H]SN56 were tested per experiment with 100 µg membrane per sample. Non-
specific binding was determined by the addition of haloperidol, at a final concentration of 100 
µM. Samples for the determination of total and non-specific binding for each experiment were 
run concurrently and filtered simultaneously. 
 
2.3.11 Competition binding assays 
For the determination of Ki for established σ ligands by competition binding, aliquots of 
membrane were incubated with [
3
H]SN56 and varying concentrations of test ligands. The 
following test compounds were evaluated: 1,3-di-o-tolylguanidine (DTG), haloperidol, (+)-
pentazocine, (-)-pentazocine and (+)-SKF10,047. For each test compound, ten concentrations 
were incubated with 0.7-0.8 nM [
3
H]SN56 with 100 µg membrane per sample. Non-specific 
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binding was determined by the addition of haloperidol, at a final concentration of 100 µM. 
Samples for the determination of total and non-specific binding for each experiment were run 
concurrently and filtered simultaneously. 
 
2.3.11 Scintillation counting and data analysis 
Following washing, filters were transferred to scintillation vials and 5 ml scintillation cocktail 
was added. Filters were allowed to soak in cocktail for a minimum of 10 h prior to counting. The 
data were analyzed using GraphPad Prism software (San Diego, CA). Saturation binding data 
were fit using nonlinear regression to a one-site model. A Hill plot of the saturation data was 
generated by linear regression of the plot of log([B]/Bmax-[B]) versus log[L], where [L] = 
radioligand concentration, and [B] = the concentration of radioligand bound at the respective [L]. 
Association kinetics data were fit using linear regression of the plot of ln(Be-B/Be) versus time, 
where Be = radioligand bound at equilibrium, and B = radioligand bound at time t; the slope of 
the plot yielded k
obs
. The association rate constant (k
+1
) was calculated using the pseudo first-
order method from the equation k
+1
 = (kobs – k
-1
) / [L]. Dissociation kinetics data were fit using 
linear regression of the plot of ln(B/B0) versus time, where B0 = specific radioligand bound at 
time of addition of haloperidol, and B = specific radioligand bound at time t. For competition 
binding data, Ki values were calculated from experimentally determined IC50 values with the 
Cheng-Prusoff equation using the Kd for [
3
H]SN56 determined from the saturation binding 
experiments (0.069 nM). For comparison of competition binding data obtained with [
3
H]SN56 to 
data obtained with [
3
H](+)-pentazocine a correlation plot was generated with the assumption that 






2.4.1 Basic binding parameters 
At near saturating conditions, non-specific binding of [
3
H]SN56 remained essentially constant in 
the presence of 25 to 200 µg membrane, suggesting that the observed non-specific binding is due 
primarily to filter binding. As shown in Figure 3, total binding was linear from 50 to 200 µg 
membrane.  
 
2.4.2 Association and dissociation kinetics 








. From the 
dissociation studies, k
-1





0.084 nM. The low dissociation rate permits the use of filtration for the separation of free from 
bound radioligand [24], while the association rate supports 90 min incubations for attaining 
steady-state binding.  
 
2.4.3 Saturation binding 
Figure 4 shows the results of the saturation binding study of [
3
H]SN56. Non-linear analysis of 
the saturation binding data fitted using a one-site model yielded a Kd = 0.069 ± 0.007 nM nM 
and a receptor density (Bmax) of 340 ± 10 fmol/mg (R
2
 = 0.96). This represents a 70-fold higher 
affinity than reported for [
3
H](+)-pentazocine (Kd = 4.8 nM) [15]. A Hill plot of the data yielded 
a slope = 1.14 with R
2
 = 0.96. A two-site fit of the saturation data yielded a “did not converge” 
message from the Prism curve-fitting software, indicating the data does not fit a two-site binding 
model. 
 
2.4.4 Competition binding 
Kis determined in this study using [
3
H]SN56 versus values determined using rat brain P2 with 
[
3
H](+)-pentazocine, processed using Brandel filtration, determined in studies detailed in Chapter 
4 of this dissertation, are shown in Table 1. In Figure 5, a comparison of binding profiles of the 




H](+)-pentazocine is shown in a correlation plot of Ki values 
obtained in this study versus the values obtained with [
3
H](+)-pentazocine. For the group of 
hallmark sigma ligands tested, there was a significant correlation between the affinities obtained 
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using the novel versus conventional radioligand (Pearson r = 0.99). Of particular note is the 
higher affinity of (+)-pentazocine as compared to (-)-pentazocine in the assays, a 




Characterization of a series of novel 2(3H)-benzothiazolone compounds in sigma receptor 
competition binding assays revealed SN56 (3-(2-(azepan-1-yl)ethyl)-6-propylbenzo[d]thiazol-
2(3H)-one) to have subnanomolar affinity and >1,000-fold selectivity for the σ1 subtype relative 
to σ2 [16]. Binding of SN56 to non-sigma binding sites was tested with a battery of receptors and 
transporters including, adrenoceptor α1, adrenoceptor α2, adrenoceptor β1, adrenoceptor β2, 
histamine H1, histamine H2, mu opioid, delta opioid, kappa opioid, dopamine D1, dopamine D2, 
serotonin 5HT2a, serotonin 5HT3, and GABAA receptors; and dopamine and serotonin 
transporters [16]. Of the binding sites tested, only α2 and H1 showed affinities greater than 1 µM 
(Ki α2 = 205 nM, and Ki H1 = 311 nM respectively) [16]; however, the affinity of SN56 for the 
σ1 receptor is approximately 350-times higher than its affinity for either of these receptors, 
indicating a favorable selectivity profile for the development of a radioprobe for use in 
radioligand binding studies.  
 
In the present study, [
3
H]SN56 exhibited >95% specific binding to σ1 receptors in rat brain 
membranes at concentrations up to 10 times the Kd. However, non-specific binding of [
3
H]SN56 
to the glass fiber filters used to separate bound from free radioligand was 25-35% at 10 times the 
Kd concentration, resulting in a final specific binding signal of 65-75% of total observed binding. 
[
3
H]SN56 exhibited saturable and reversible binding to a single high affinity site in rat P2 
membranes with a binding profile similar to that observed for [
3
H](+)-pentazocine. The Bmax 
observed for [
3
H]SN56 (340 ± 10 fmol/mg) was consistent with the range of values reported in 






H](+)-pentazocine [25, 26]. 
The Hill plot of the saturation binding data, which describes the fraction of receptor saturatation 
as of function of radioligand concentration, yielded a slope of 1.14, suggesting there was no 
cooperativity in binding of [
3
H]SN56. In addition, the Ki values of established sigma receptor 
ligands determined by competition binding versus [
3
H]SN56 were consistent with those reported 
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in the literature against the well established σ1 radioligand [
3
H](+)-pentazocine [15]. 
Furthermore, the association and dissociation kinetics of [
3
H]SN56 were shown to be amenable 
to two hour incubations, and filtration for separation of free from receptor bound radioligand. 
 
Yous et al. [16] reported a Ki of 0.56 nM for SN56 versus [
3
H](+)-pentazocine in P2 membranes 
prepared from guinea-pig brain. Similarly, we obtained a Ki of 0.38 nM versus [
3
H](+)-
pentazocine in P2 membranes prepared from rat brain (data not shown). These values are ~5 fold 
higher than the affinity determined with saturation and kinetic studies of [
3
H]SN56 (~0.07 nM 
and ~0.08 nM respectively. We suspect that depletion of the non-labeled ligand results in an 
erroneously high value for the Ki of SN56 as determined by competition binding.      
 
While most researchers are familiar with radioligand depletion due to excessive receptor 
concentration, depletion of the unlabeled ligand occurs when the affinity of the unlabeled 
compound greatly exceeds the affinity of the labeled compound [27, 28]. Goldstein et al. [28] 
used computer modeling to derive estimates of the error in the determination of the Ki of ligands 
exhibiting higher affinities than the radioligands utilized in their measurement; the authors 
projected that for an unlabeled ligand with a true affinity 100 times greater than the radioligand 
(as in our case), 10% radioligand depletion would result in an experimentally determined Kd ~6 
times higher than the true value. Thus, the ~5-fold difference between the affinity of SN56, as 
determined by competition binding, and the affinity of [
3
H]SN56 determined with saturation and 
kinetic studies may be explained by this phenomena. 
 
Systematic errors resulting from the use of high receptor concentrations may also contribute to 
errors in both the determination of Kd from saturation and kinetic experiments, and in the 
determination of Kis of unlabeled compounds. However, these errors are minimal, quantifiable, 
and in practice when [
3
H]SN56 is used for competition binding assays of σ1 ligands, our 
preliminary results suggest they have no impact on our Ki determinations as compared to 
historical data for the compounds tested 
 
Practical considerations dictated that we use relatively high receptor concentrations; this 
introduces systematic error that is quantifiable and within acceptable limits. When possible, 
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experimental conditions for binding experiments should be chosen so that the receptor 
concentration is less than 10% of the Kd of the radioligand to minimize radioligand depletion 
[27]. However, with a radioligand with subnanomolar affinity this would require multi-milliliter 
sample volumes. Our experiments required 100 µg of tissue to obtain adequate signal for precise 
detection. We chose 0.5 ml sample volumes because we intend to adapt this method to a higher 
throughput 96-well method where sample volumes are more limited than in test tube based 
binding determinations. To ensure that >90% of added radioligand was “free” (unbound) in 
competition binding experiments run under these conditions we utilized high concentrations of 
[
3
H]SN56. While these conditions are not ideal they are tolerated if required for detection and the 
error in values obtained with the method are known and within an acceptable range as 
determined by the researcher’s requirements [29]. 
 
Carter et al. [29] examined the effects of assay miniaturization using the human muscarinic M3 
receptor expressed in CHO (Chinese hamster ovary) cells. This cell line expressed the M3 





scopolamine methyl chloride), had an affinity of 41 pM [29]. In their saturation binding studies 
they varied receptor concentrations over a wide range, with membrane amounts from 5-50 µg in 
volumes from 50-1750 µl, resulting in ratios of receptor concentration ([receptor])/Kd from 0.35-
122 [29]. They found that as the volume was decreased or the amount of membrane was 
increased the calculated Kd and Bmax increased [29]. When no corrections were made for 
radioligand depletion, with [receptor]/Kd = 0.35 (the lowest ratio tested, corresponding to 5 µg in 
1750 µl) they calculated the Kd to be approximately 2.4 times the “true” value and with 
[receptor]/Kd = 12.2 (5 µg in 50 µl) they calculated the Kd to be approximately 4.6 times the true 
value [29]. When the Kds were recalculated, taking into account radioligand depletion, the 
resulting values were 2.3 and 3.0 times the true value, respectively [29]. Therefore, practitioners 
should be aware that experimental conditions resulting in excessive radioligand depletion will 
yield an overestimate of the true Kd even if depletion is accounted for. 
 
The conditions chosen for our saturation studies utilized a [receptor]/Ki of ~ 0.25. No corrections 
were made for radioligand depletion because it was not possible to accurately assess what 
portion of non-specific binding was due to binding to membrane versus binding to filter. Based 
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on Carter’s work [29] we might expect our results to overestimate the Kd of [
3
H]SN56 by ~3-
fold. Carter’s studies [29] of competition binding utilizing conditions of excessive radioligand 
depletion did not model the conditions we utilized, with [receptor] = ~0.1 nM and concentration 
[
3
H]SN56 = ~1.5 times the Ki of SN56, so direct comparisons of our competition binding data to 
their data are not possible. However, as stated previously, the Ki values we derived for the sigma 
receptor ligands tested correlated well with values reported in the literature.  
 





H]SN56 for the ligands tested. A larger pool of compounds should be 
screened to confirm that this relationship is maintained. If compounds are identified that yield 




H]SN56, such a result would 
suggest that σ1 receptors support multiple binding modalities.  
 
Future advances in the field of sigma receptor therapeutic development will require greater 
knowledge of the nature of the interaction of sigma receptors with ligands and protein binding 
partners. Additional tools needed to further this knowledge include new subtype-specific agonist 
and antagonist ligands, radioligands, and other affinity labels and probes. The development of 
other technologies, such as high throughput methods for the determination of binding affinities, 
and in vitro functional assays, will also hasten efforts to design and identify new selective sigma 
ligands with potential therapeutic value.   
 
In conclusion, the results of our studies show that [
3
H]SN56 possesses high affinity and 
selectivity for the σ1 receptor, and appears to be a viable alternative for [
3
H](+)-pentazocine in 
radioligand binding assays. [
3
H]SN56 demonstrated saturable and reversible binding to a single 





H]SN56 represents a valuable tool for the study of the σ1 receptor 
and the development of σ1 receptor based therapeutics. Additional studies of [
3
H]-SN56 are 
warranted to confirm the results observed in this study and more fully characterize its interaction 
with the σ1 receptor. Proposed additional studies include: 1) expanding the number of ligands 





pentazocine, and 2) confirming that SN56 competitively inhibits the binding of [
3
H](+)-
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Figure 1. Structures of SN56, [
3



































Figure 2. Synthesis of brominated [
3
H]SN56 precursor 4 :  a) Propionyl chloride, AlCl3, 85 C ; 
b) (C2H5)3SiH, CF3COOH, RT; c) Br2, CH3COOH, RT; d) 2-(hexamethyleneimino)ethylchloride 


















Figure 3.   Binding linearity for [
3
H]SN56 with rat brain P2 membranes. Samples contained 0.7 
nM [
3
H]SN56, in a total volume of 0.5 ml. Non-specific binding (NSB) was determined by the 
addition of 100 µM haloperidol. Data points represent the mean of three independent 
determinations of duplicate samples at each membrane concentration. The data point at 300 µg 
rat brain P2 deviates from the linear binding observed from 50-200 µg. 








































Figure 4. Saturation binding of [
3
H]SN56 with rat brain P2 membranes. Samples contained 100 
µg membrane in a total volume of 0.5 ml. Data points represent the mean ± SEM of three 
independent determinations of duplicate samples at each concentration. Bmax = 340 ± 10 




































Table 1. Summary of data from competition binding experiments. The Ki values determined 
with [
3
H](+)-pentazocine were obtained using rat brain P2 processed by Brandel filtration as 










287 ± 36289 ± 6(+)-SKF10,047
57.4 ± 3.341.6 ± 8.8DTG
57.2 ± 1.977.0 ± 9.0(-)-pentazocine
8.7 ± 0.45.7 ± 1.0(+)-pentazocine






















Figure 5. Comparison of Ki values determined with [
3
H]SN56 versus values determined with 
[
3
H](+)-pentazocine as detailed in Chapter 4 of this dissertation. Pearson r = 0.99. 1, haloperidol; 
2, (+)-pentazocine; 3, (-)-pentazocine; 4, DTG; 5, (+)-SKF10,047. 
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A 96-well filtration method for radioligand binding 





3.1 Abstract   
 
Sigma receptors represent a potential drug target for numerous therapeutic indications including 
cancer, depression, psychostimulant abuse, and stroke. To date, no in vitro assays have been 
developed which are amenable to routine use for determining the functional activity of novel 
sigma ligands. As a result, radioligand binding assays are currently used as a primary screen to 
identify promising candidates for in vivo studies. Most published radioligand binding studies for 
sigma receptors utilize a low throughput method employing a “cell harvester.” Higher 
throughput methods are required to facilitate more efficient screening of the large numbers of 
novel compounds our laboratory routinely analyzes for binding to sigma receptors. This study 
compared binding affinities determined with a new medium-throughput 96-well filtration method 
to results obtained using the conventional cell harvester-based method. The 96-well assay 
utilized rat liver membranes for the determination of both known sigma receptor subtypes (σ1 
and σ2) because this tissue contains high densities of both subtypes and fulfils criteria required 
for reliable use with the 96-well format. The new method was shown to give comparable Ki 
values for reference ligands, and a novel series of 2(3H)-benzothiazolone compounds, analyzed 
in parallel with samples prepared in rat brain membranes and processed on the traditional cell 
harvester. For σ1 receptors equivalent affinity values were observed for both methods/tissues. 
For σ2 receptors, approximately 2-fold higher affinities were observed for most compounds in 
liver membranes as compared to brain membranes but excellent correlation with brain-derived 
values was maintained. Analysis of the 2(3H)-benzothiazolone series identified several new 
compounds with nanomolar affinity and greater than 50-fold specificity for σ1 versus σ2 
receptors. Further, because dramatic differences in subtype binding were observed in this 
synthetic series, this study also provided useful data for the continued development of 





The sigma receptor was first described as an opioid receptor subtype based on the behavioral 
effects of N-allylnormetazocine (SKF-10,047) in dogs [1]. Subsequent in vitro radioligand 
binding studies revealed that the binding site for prototypic sigma ligands was a protein distinct 
from opioid receptors [2, 3]. Currently, two subtypes of sigma receptors are recognized, σ1 and 
σ2; these subtypes can be distinguished by differences in ligand selectivity, tissue distribution 
and molecular properties. Because sigma receptors are recognized as potential therapeutic and 
radioprobe targets, research to ascribe in vitro and in vivo activities to the respective subtypes is 
a major focus of sigma receptor research [4-8]. Consequently, to facilitate these studies, efforts 
to synthesize and identify novel subtype selective agonist and antagonist compounds are 
ongoing.  
 
There are currently no accepted in vitro assays for routinely testing sigma receptor ligand 
activities; therefore, radioligand binding serves a critical role in screening novel ligands. 
Radioligand competition binding assays using a conventional cell harvester represent a 
bottleneck in the development of new sigma ligands due to the low throughput nature of the 
format. 96-well filtration offers the potential to increase throughput and reduce costs for routine 
radioligand binding assays.  
 
Previous reports of the use of 96 well filtration methodologies for the analysis of sigma receptor 
binding are limited to two research groups [9-14]. The Mach group from Washington University 
were the first to report the use of 96-well filter plates for the analysis of sigma receptor binding 
[11]. In these initial studies binding to σ2 receptors in crude rat liver homogenate, and in human 
and mouse tumor xenografts was examined with [
3




hyl-benzamide). Later studies extended the technique to the determination of σ1 affinities in 
guinea-pig brain membranes labeled with [
3
H](+)-pentazocine [9, 13, 14]. A more recent study 
reported by the Wünsch group from the University of Münster examined binding at both sigma 
subtypes utilizing “filtermats,” an alternative filter format designed for 96-well use [10]. The 
results of these studies suggested that 96-well filtration is a viable approach for separation of free 
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from receptor bound radioligand for sigma receptor binding studies. However, to support future 
routine use of the 96-well filtration based process, additional confirmation that results obtained 
using the method produces results equivalent to the more established cell harvester-based 
methods is needed.  
 
The majority of contemporary sigma receptor binding studies are performed with P2 membranes 
prepared from guinea-pig brain for assaying σ1 receptor binding, and rat liver P2 membranes for 
assaying σ2 receptors, because these tissues are enriched in the respective subtypes [9, 10, 15, 
16]. Reported values for Bmax of σ1 in rodent brain P2 vary, ranging from approximately 300 to 
500 fmol/mg for rat brain [17, 18], and approximately 575 fmol/mg to 2.0 pmol/mg, for guinea-
pig brain [19-22]. The published Bmax value for σ2 receptors in rat liver P2 is ~9 pmol/mg [23].  
 
Receptor expression levels of 2 pmol/mg or greater are required for detection with tritiated 
ligands and the typical sample sizes of 2-100 µg total protein per well used in 96-well filtration 
assays [24-26]. This requirement is due to the limited filtration capacity of 96-well filter plates 
and the relatively low specific activity of tritium. Because the reported expression level for σ1 
receptors in guinea-pig brain varies and the highest reported level of 2.0 pmol/mg [19] just meets 
the minimum criteria for processing by 96-well filtration we sought a tissue with greater σ1 
receptor expression levels.  
 
Rat liver P2 contains high densities of both subtypes of sigma receptors [23, 27, 28]; 
representative Bmax values determined for σ1 and σ2 are ~3 pmol/mg and ~9 pmol/mg 
respectively [23]. It has also been reported that rat brain and rat liver homogenates yield similar 
affinity values for binding of σ1 reference ligands [28-30], and as stated previously, rat liver is 
already the established preferred tissue for σ2 binding studies [31]. Rat liver was thus chosen for 
development of this assay. 
 
Despite the reported equivalency of rat liver and rat brain membranes for the determination of σ1 
binding [28-30] it was necessary to rigorously demonstrate that the two tissues would yield 
similar results in our hands using the 96-well filtration platform. Uncharacterized differences in 
lipid composition, protein partners, and cellular distributions of σ1 in P2 isolates of the two 
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tissues may introduce unanticipated artifacts that impact affinity measurements. Known 
differences in lipid compositions of whole organ homogenates of rat liver compared to rat brain 
include: 1) higher amounts of phosphatidylcholine in liver, 2) higher amounts of 
phosphatidylethanolamine in brain, and 3) the presence of cerebrosides and sulfatides in brain 
that are not found in liver [32]. The relative distribution of these lipids in P2 membranes isolated 
by our methods has not been reported; therefore, it is not known if the differences observed in 
whole tissue homogenates are reflected in this fraction.    
 
Determinations of σ2 binding may also be influenced by differences in lipid composition or 
protein partners in the two tissues. Because σ2 receptors reside in lipid rafts, and behave very 
differently to detergent extraction relative to σ1 receptors [33, 34], lipid composition differences 
in the two tissues may be an important consideration. Despite the continued use of brain tissues 
by some researchers for the determination of σ2 receptor binding affinities [35-38], there have 
been no rigorous comparisons of binding at σ2 in brain versus liver membranes. Furthermore, it 
has not been conclusively established that σ2 receptors present in the brain are the same protein 
as those found in liver.  
 
Extending on earlier work by Ucar et al. [39], Yous et al. [40] reported a structure-binding 
affinity study for a small series of benzothiazolone compounds with high affinity and specificity 
for sigma receptors. In this study they identified SN56 (3-(2-(azepan-1-yl)ethyl)-6-
propylbenzo[d]thiazol-2(3H)-one) as a new sigma receptor specific ligand with nanomolar 
affinity and unprecedented selectivity for the σ1 versus the σ2 subtype and versus a battery of 
non-sigma receptors and neurotransmitter transporters [40]. More recent in vivo and in vitro data 
suggested SN56 as a promising lead compound for further investigations of additional 2(3H)-
benzothiazolone analogues [41]. We have shown that [
3
H]SN56 yields a similar pharmacological 
profile compared to the universally accepted σ1 radioprobe, [
3
H](+)-pentazocine [41]. 
Additionally, behavioral studies performed in our laboratory demonstrated that SN56 protected 





In the present report, in addition to a series of reference compounds, a series of novel 2(3H)-
benzothiazolone compounds were analyzed for binding to sigma receptors to validate the method 
for routine use. The reference compounds used in this study represent known sigma ligands with 
well-established pharmacological characteristics. The 2(3H)-benzothiazolone compounds 
examined included variations in: 1) the size of the attached heterocycle, 2) the heterocycle linker 
chain length, and 3) the composition of the alkyl or acyl chain at position 6 of the 2(3H)-
benzothiazolone system. Following successful demonstration that the proposed 96-well method 
gave satisfactory results with the reference compounds, the binding affinities of the 2(3H)-
benzothiazolone compounds for sigma receptors were determined. 
 
Because radioligand binding assays serve a significant role in identifying new sigma ligands and 
current methods do not meet our current throughput needs, we sought to develop a higher 
throughput method. We chose to examine a 96-well filtration format and evaluated the procedure 
with reference ligands and analogues of the 2(3H)-benzothiazolone compound, SN56. The 
method employed rat liver membranes for the determination of binding at both σ1 and σ2 
receptors. Binding affinities determined with this new method were compared to measurements 
generated using conventional filtration to qualify the validity of this new approach for routine 
screening of novel sigma ligands.  
 
3.3 Materials and Methods  
 
3.3.1 Chemicals and Reagents 
[
3
H](+)-Pentazocine (specific activity = 29 Ci/mmol) and [
3
H]DTG (specific activity = 53.3 
Ci/mmol) were purchased from Perkin Elmer (Boston, MS). (+)-Pentazocine, (-)-pentazocine, 
(+)-N-allylnormetazocine hydrochloride, 1,3-di-o-tolylguanidine (DTG), haloperidol,  
progesterone, dextromethorphan hydrobromide, rimcazole dihydrochloride monohydrate, 
sucrose, NaCl, dimethylsulfoxide (DMSO) and tris(hydroxymethyl)aminomethane (Tris), were 
purchased from Sigma-Aldrich (St. Louis, MO). NE100 (4-methoxy-3-(2-phenylethoxy)-N,N-
dipropylbenzeneethanamine hydrochloride), BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-
methylpiperazine dihydrochloride), and fluvoxamine maleate were obtained from Tocris 
Bioscience (Ellisville, MO). AC927 (N-phenethylpiperidine oxalate) was provided by Dr. 
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Andrew Coop from the University of Maryland (Baltimore, MD). SN56 (3-(2-(azepan-1-
yl)ethyl)-6-propylbenzo[d]thiazol-2(3H)-one) and the RB compound series (see Table 2) were 
provided by the laboratory of Dr. Christopher McCurdy from the University of Mississippi 
(University, MS). Coomassie Protein Assay reagent, 1N hydrochloric acid, glacial acetic acid, 
Ecoscint, Microscint 20, Brandel GF/B filter papers, 2.25 x 12.25 inches, and Unifilter-96 GF/B 
filter plates were purchased from Fisher Scientific (Pittsburgh, PA).  
 
3.3.2 Membrane preparation  
Rat brain P2 and rat liver P2 fractions were prepared as described previously and outlined below 
from frozen tissues obtained from Pel-Freeze (Rogers, AR) [46]. Tissues were homogenized 
batch-wise with a Potter-Elvehjem homogenizer (5-10 strokes with motor driven Teflon pestle) 
in ice-cold 10 mM Tris-sucrose buffer (0.32 M sucrose in 10 mM Tris, pH 7.4) using 10 ml 
buffer per g of tissue with ~3 g of tissue per batch. Homogenates from multiple batches were 
combined and centrifuged for 10 min at 1,000 x g, at 4 °C. Supernatants were decanted, 
combined and centrifuged for 15 min at 31,000 x g, 4 °C. To reduce levels of bound endogenous 
ligand(s) the resulting P2 membrane was washed as follows: 1) pellets were re-suspended in 10 
mM Tris, pH 7.4 using 3 ml buffer per g of wet tissue, 2) the resulting suspension was incubated 
for 30 min at 25 °C, 3) following incubation, the suspension was centrifuged for 15 min at 
31,000 x g, at 4 °C. The resulting pellets were re-suspended in 10 mM Tris, pH 7.4 buffer at a 
final concentration of 1 g starting tissue weight/1.5 ml. Tissue preparations were aliquoted in 1 
ml portions and stored at -80 °C. The Bradford assay was used to quantitate protein 
concentration (Bradford, 1976).   
 
3.3.3 96-well filtration with rat brain membrane 
The 96-well filtration method was tested with rat brain P2 membranes to confirm that this 
material was incompatible with processing using the 96-well filtration plates. Samples were 
prepared and processed as described below for competition binding assays of rat liver processed 
by 96-well filtration except samples contained 25, 50 or 100 µg/well rat brain P2 membrane 
instead of rat liver P2 membrane. Each membrane concentration was assayed in triplicate for 
total and non-specific binding. Full sample plates containing 100 and 200 µg/well were also 
prepared and processed to confirm that the results of the samples described above were not 
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compromised by loss of vacuum pressure due to the use of varied membrane concentrations in 
individual test wells. These samples were prepared in a total volume of 0.5 mL/well to more 
faithfully duplicate typical samples prepared for filtration using the Brandel harvester.  
    
3.3.4 Binding linearity with rat liver membranes processed by 96-well filtration 
To determine the appropriate amount of rat liver membrane to use in competition binding assays 
processed by 96-well filtration, binding linearity studies were performed for both sigma receptor 
subtypes. Samples were prepared and processed as described below for competition binding 
assays. Samples contained 0, 10, 20, 30, 40, 50, or 60 µg/well rat liver membrane. Each 
membrane concentration was assayed in triplicate for total and non-specific binding.     
 
3.3.5 Competition binding assays  
To test the suitability of the 96-well filtration method for routine use in determining sigma ligand 
binding affinities, a series of sigma reference ligands were assayed using the 96-well method and 
re-assayed using the conventional cell harvester-based method. Following successful 
demonstration of the correlation between the two processes, a series of 2(3H)-benzothiazolone 
compounds were assayed with the 96-well filtration method.  
 
Radioligand binding assays utilized optimized buffer and incubation conditions that are 
consistent with those reported in the literature for the analysis of sigma receptor binding [20, 23, 
47]. Stock solutions of test ligands were prepared in DMSO or deionized water at 5 or 25 mM. 
Dilutions of reference ligands for competition studies were made with assay buffer (50 mM Tris, 
pH 8). Dilutions of 2(3H)-benzothiazolone analogues were prepared in 1 mM HCl. The use of 1 
mM HCl for dilution of 2(3H)-benzothiazolone analogues was required to reduce binding of 
these compounds to glass tubes or polypropylene microplates and had no effect on the final pH 
of the samples or on total binding relative to samples prepared in assay buffer alone (data not 
shown). For samples requiring DMSO for solubilization, a final concentration of up to 1-2% 
DMSO in assay samples had no effect on total binding. 
 
Assays with rat brain were processed using a Brandel R48 harvester (Gaithersburg, MD), and 
assays with rat liver were processed using a Connectorate 96-well harvester (Dietikon, 
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Switzerland). For compounds assayed with brain homogenate, 400 µg of rat brain P2 membrane 
was added to a glass test tube containing test ligand and radioligand in assay buffer in a final 
volume of 0.5 ml. For compounds analyzed with rat liver homogenate, 40 µg of rat liver P2 
membrane was added to a polypropylene plate (catalogue number 07-200-697, Fisher Scientific) 
containing test ligand and radioligand in assay buffer in a total volume of 0.25 ml. 
 
Assays for σ1 receptors used a final concentration of 5 nM [
3
H](+)-pentazocine. Labeling of σ2 
was effected with either 3 nM [
3
H]DTG for brain membranes, or 5 nM [
3
H]DTG for liver 
membranes; these samples also contained 300 nM (+)-pentazocine (to block σ1 receptors). The 
concentrations of radioligand stock solutions were calculated based on CPM measurements and 
specific activities reported by the manufacturer. Nonspecific binding (NSB) was determined by 
the addition of haloperidol to a final concentration of 10 µM. Samples were incubated for 120 
min at 25°C for all assays. Samples prepared in test tubes and processed with the Brandel 
harvester were vortexed prior to incubation; samples prepared in microplates for 96-well 
filtration were agitated during incubation on a 96-well plate shaker. Following incubation, 
samples were filtered and washed. Samples processed on the Brandel cell harvester were washed 
3 times with 3 ml of 10 mM Tris, pH 8. Samples processed by 96-well filtration were washed 5 
times with 0.2 ml of 10 mM Tris, pH 8. Prior to use GF/B filter papers and Unifilter GF/B filter 
plates were soaked in 0.5% polyethyleneimine (PEI) for 30 min to reduce non-specific binding.  
 
For the determination of binding affinities, each test compound was assayed at 11 concentrations 
varying from 0.001 – 10 µM. Samples were prepared and processed in duplicate for each binding 
curve and triplicate determinations of binding curves were made for each compound. Samples 
for the determination of total and non-specific binding for each experiment were run 
concurrently and filtered simultaneously. Following washing, filters processed on the Brandel 
harvester were transferred to scintillation vials and 3 ml scintillation cocktail was added to each 
sample. Filters were allowed to soak in cocktail for a minimum of 10 h prior to counting on a 
Beckman LS6500 scintillation counter (Brea, CA). Samples processed by 96-well filtration were 
counted on a Perkin Elmer Microbeta2 2450 microplate counter (Waltham, MA), in the Unifilter 





3.3.6 Data analysis  
The competition binding data were analyzed with GraphPad Prism software (San Diego, CA) 
using a one-site nonlinear regression model to determine the concentration of ligand that inhibits 
50% of the specific binding of the radioligand (IC50 value). Ki values were calculated from the 
IC50 using the Cheng-Prusoff equation [48]. To compare binding data from conventional binding 
experiments to the 96-well filtration method, correlation plots were generated with GraphPad 
Prism, using a two-tailed fit with the assumption that data were sampled from Gaussian 
populations (Pearson r). For comparison of individual Ki values obtained using rat liver versus 
rat brain a two-tailed t-test was performed using InStat software (San Diego, CA). Hill plots of 
competition binding data were determined with GraphPad Prism software using the "sigmoid 
dose-response (variable slope)" equation. Partition coefficients adjusted for pH (logD) were 




3.4.1 96-well filtration with rat brain membrane 
Samples of rat brain membrane were prepared and processed using the 96-well filtration format 
to confirm that this material did not contain high enough expression levels of σ1 receptors to be 
compatible with analysis by this method. Percent non-specific binding (% NSB) for 0, 25, 50 and 
100 µg membrane/well was 93%, 92%, 76% and 59% respectively. Wells containing 100 µg 
membrane/well appeared to clog as evidenced by incomplete emptying of wash solution from the 
sample plate. The full plates prepared with 100 or 200 µg membrane/well also appeared to clog 
with membrane; despite the appearance that the samples transferred to the filters, washing was 
not possible.    
 
3.4.2 Binding linearity with rat liver membranes 
To determine the appropriate amount of rat liver P2 membrane to use in competition assays with 
96-well filtration, a binding linearity study was performed for both receptor subtypes using 





H]DTG (in the presence of 300 nM (+)-pentazocine) increased 
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linearly from 0 to 50 µg rat liver P2 membrane (total protein) added per well. Non-specific 
binding also increased linearly and remained a constant percent of total binding throughout the 
linear range of total binding. For σ1 receptors non-specific binding was 15-20% of total binding; 
for σ2 receptors, non-specific binding was 10-15% of total binding. For σ2 binding assays a 
titration experiment confirmed that 300 nM (+)-pentazocine was sufficient to adequately block 
σ1 receptors without significantly impacting σ2 binding. Based on these results competition 
binding studies for all compounds analyzed by 96-well filtration utilized 40 µg liver membrane 
per well. This amount of membrane ensured that <10% of added radioligand bound to sigma 
receptors (in this case radioligand binding was <3-4% of added label), a requirement for 
application of competition binding algorithms based on the laws of mass action [49]. Non-
specific binding for samples prepared with rat brain and processed with the Brandel harvester 
averaged 40-50% for σ1 receptors and 30-40% for σ2 receptors. 
 
3.4.3 Binding affinities of reference ligands 
Sigma receptor binding affinities for individual reference compounds as reported in the literature 
and as determined in this study are shown in Table 2 and Table 3, for σ1 and σ2 receptors 
respectively. Overall, values obtained for sigma binding in rat brain P2 from this study were 
similar to values reported in the literature, where measurements were made with similar 
experimental conditions in either rat or guinea-pig brain fractions (see legend to Table 2). 
Likewise, similar σ1 binding affinities were observed for samples analyzed in this study with 
liver P2 versus brain P2 for all reference compounds with the exception of those compounds 
with low affinity: progesterone, dextromethorphan and rimcazole; these compounds showed 
statistically significant higher affinities in liver as compared to brain (progesterone, P < 0.001; 
dextromethorphan, P < 0.005; rimcazole, P < 0.001). At σ2 receptors, all compounds tested 
showed higher affinity in liver versus brain, with most compounds displaying an approximately 
2-fold higher affinity in liver compared to brain; the difference was statistically significant, for 
six of the ten compounds tested (DTG, P < 0.005; haloperidol, P < 0.001; NE100, P < 0.001; 
BD1063, P < 0.001; AC927, P < 0.005; and fluvoxamine, P < 0.005). Figure 3A shows 
correlation plots for σ1 binding in rat liver P2 versus rat brain P2 as determined in this study 
(Pearson r = 0.97), and Figure 3B shows binding in rat brain P2 versus literature values for rat or 
guinea-pig brain membranes (Pearson r = 0.95). Figure 4A shows a correlation plot for σ2 
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binding in rat liver P2 versus rat brain P2 as determined in this study (Pearson r = 0.98), and 
Figure 3B shows binding in rat brain P2 versus literature values for rat or guinea-pig membranes 
(Pearson r = 0.95). Pearson r values for these plots indicate that binding is proportional over a 
four log range of Ki values for σ1 receptors and an approximately two and a half log range for σ2 
receptors in rat liver P2 versus rat brain P2. 
 
3.4.4 Binding affinities of 2(3H)-benzothiazolone analogues 
Sigma receptor binding affinities determined in this study for individual test compounds are 
shown in Table 4. The parent compound structure is shown in Figure 5 where R represents the 
appended alkyl or ketonyl chain, m represents ring size, and n represents linker chain length.  
Some general trends observed include: 1) a reversal in selectivity from σ1 to σ2, for azepine ring 
compounds (m = 2) with increasing linker arm length (from n = 2 to n = 5), reflecting marginal 
changes in affinity at σ1 and significant increases in affinities for the σ2 subtype, 2)  reduced 
affinity for both sigma subtypes when the azepine ring of SN56 was replaced with a pyrrolidine 
ring (m = 0), as demonstrated by RB65 and RB75, and 3) a dramatic decrease in σ2 affinity with 
a marginal change in σ1 affinity for linker length n = 1, with an azepine ring, and a change of the 
chain at position 6 from (CH2)2CH3 to COCH2CH3, as demonstrated by SN56 and RB74. The Ki 
σ2/Ki σ1 value of 483 for RB74 versus 168 for SN56 represents an approximately 3-fold 
improvement in σ1 selectivity, primarily due to an almost 8-fold decrease in affinity at σ2 for 
RB74 versus SN56.  
 
3.4.5 Pseudo-Hill coefficients for competition binding curves  
Pseudo-Hill coefficients (pseudo-nH) were calculated to determine if the competition binding 
data was consistent with a reversible bimolecular interaction following the laws of mass action  
[50, 51]. No samples yielded a pseudo-Hill coefficient significantly different from unity; no 
deviations greater than 0.15 were observed.  Where a sample deviated greater than 0.1 from unity 
visual inspection of the curve overlaid with a curve generated with the slope constrained to unity 
suggested the calculated value was anomalous. Because the pseudo-Hill coefficient describes the 
equilibrium between both the labeled and unlabeled compounds with the receptor, small 




3.4.6 Binding affinity versus lipophilicity for 2(3H)-benzothiazolone analogues 
To determine if there was a correlation between the lipophilicity of the appended R group at 
position 6 on the 2(3H)-benzothiazolone base structure, and binding affinity among homologues 
with similar linker chain lengths, a plot of log Ki versus logD was generated. LogD was 
calculated using ACD Labs software and are tabulated for pH = 8 because this was the pH used 
for the binding determinations. The results for all compounds are shown in Table 7. The plot of 
log Ki versus logD for the homologous compounds is shown in Figure 6. For n=2 a change in the 
R group from H to (CH2)2CH3 resulted in a change in logD from 1.52 to 2.82 with a concomitant 
10-fold increase in affinity at σ2. Similarly for n=3 the change from H to (CH2)2CH3 resulted in a 
change in logD from 1.47 to 2.60 with a concomitant 23.5-fold increase in affinity at σ2. For n=2 
a change from (CH2)2CH3 to (CH2)3CH3 resulted in a change in logD from 2.82 to 3.14 that 
resulted in almost no change in affinity from Ki = 17.2 to 15.3 nM. A similar effect was observed 
with the n=3 compounds. For n=4 and n=5 the transition from H to (CH2)2CH3 to (CH2)3CH3 
resulted in significant increases in log P with insignificant changes in Ki. When the R group was 
changed from COCH2CH3 to CO(CH2)2CH3 insignificant changes were observed in Ki with an 
increase of logD from 2.23 to 2.72 for n=2, 2.16 to 2.25 for n=3, 1.7 to 2.47 for n=4 and 2.37 to 





In this study a 96-well method for radioligand competition binding was evaluated for routine use 
in the determination of sigma ligand binding affinities. The results for binding of reference 
ligands to rat liver P2 membranes analyzed with the 96-well method demonstrated excellent 
correlation with values derived in rat brain P2 membranes assayed using the conventional 
Brandel-based method, for both σ1 and σ2 receptor subtypes. These results suggest that 96-well 
filtration is a suitable alternative to Brandel filtration for the analysis of sigma receptor 
radioligand binding. Application of the assay to the analysis of a novel series of 2(3H)-
benzothiazolone compounds identified several new σ1 selective analogues and provided 
structure-binding affinity data that distinguish structural features which confer subtype 
selectivity for this compound class. Our data also showed that σ2 receptors derived from rat liver 
P2 appear to exhibit higher affinity for sigma ligands than those isolated from rat brain P2, a 
result that has not been previously reported. The source of this difference is unknown but should 
be considered when comparing relative binding to σ1 versus σ2 receptors where binding 
determinations are made in homogenates from different tissues.   
 
The 96-well method detailed here is an adaptation of the approach commonly described in the 
literature for analysis of sigma receptor competition binding, where typical studies utilized a 
Brandel “cell harvester” for separation of free from bound radioligand. Conversion of the method 
to a 96-well format was proposed to facilitate greater throughput in our routine sigma receptor 
binding screens of new putative sigma ligands. Adaptation of the conventional method for 
radioligand binding assays of σ1 receptors to the 96-well method required the use of rat liver 
membranes instead of the more commonly used rat or guinea-pig brain derived P2 membranes. 
This requirement was necessitated by filtration capacity limitations imposed by the 96-well filter 
configuration as well as additional considerations related to improving reproducibility for 
medium throughput screening as discussed below. 
.  
Our studies with rat brain membranes processed by 96-well filtration indicated that 100 µg of rat 
brain P2/sample well resulted in clogging of the 96-well filterplates, and lower amounts of 
membrane did not generate adequate signal for reliable measurements. In contrast, the 96-well 
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assay using rat liver membranes only required 40 µg of membrane to achieve adequate signal, 
and >60-80 µg resulted in radioligand depletion. We did not test guinea-pig brain P2 because 
reported values of σ1 expression in this tissue were variable and the highest reported value of 2 
pmol/mg [21] just met the minimum criteria for use with tritiated radioligands and the sample 
size limitations imposed by the 96-well filterplates. Additionally, as outlined below it was our 
desire to utilize one tissue for assaying both receptor subtypes and neither guinea-pig nor rat 
brain contain adequate levels of σ2 receptors to support this goal. 
 
We did not observe significant differences in binding affinities for σ1 receptors between the two 
assay methods for the majority of reference ligands tested. Because the σ1 receptor protein 
appears well conserved among species and there is no evidence for differences in the protein in 
brain versus liver, the choice of liver as a source of σ1 receptors was not expected to greatly 
impact affinity measurements [28, 52-56]. Moreover, binding studies with different crude 
membrane preparations, sub-cellular fractions and solubilized extracts derived from brain and 
liver from rat and guinea-pig, indicate that affinities of ligands for σ1 remain essentially constant 
despite the varied sources of receptors [23, 27-30, 57-59]. However, the cell biology of sigma 
receptors is still being elucidated and previously undetected differences may exist so a 
systematic comparison was needed. The observation that the low affinity compounds, 
progesterone, dextromethorphan and rimcazole, showed statistically significant higher binding 
affinities in liver membranes versus brain membranes is in agreement with previous observations 
reported by Klouz et al. [29, 30]; however, the source of this difference is unknown. 
 
Our observation that most of the reference ligands tested bound with higher affinity to σ2 
receptors isolated from liver compared to brain was unexpected. The differences were 
statistically significant for six of the ten compounds tested. While conclusive evidence for the 
source of the observed differences is lacking, we propose three possible factors that may 
contribute to ligands showing higher affinity in liver relative to brain: 1) differences in lipid 
and/or protein partners associated with σ2 in the two organ isolates, 2) the existence of 
unidentified heterogeneous populations of σ2-like receptors, with similar binding properties, that 
cannot be discriminated with existing techniques, and 3) an assay artifact due to an 
approximately 3.5-fold  higher receptor concentration employed in liver membrane assays versus 
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brain membrane assays. It should also be noted that because the σ2 receptor has not been purified 
to homogeneity, it has not been established that σ2 receptors present in the brain are the same 
protein as σ2 receptors found in the liver.    
 
A few points are worth noting regarding the apparent difference in binding affinity for σ2 
receptors from liver P2 versus brain P2 membranes. Published studies show that σ2 receptors 
reside in lipid rafts [33, 34], and differences in binding of [
3
H]DTG (with σ1 blocking) have 
been observed in partially solubilized rafts isolated from the rat liver P2 fraction using different 
detergents (Kd = ~23 nM in 20 mM CHAPS versus Kd = ~170 nM in 1% Triton X-100) but fully 
solubilized preparations in these same detergents showed equivalent binding affinities [33, 34]. 
This suggests that the binding affinity of σ2 can be influenced by manipulating the composition 
of lipids and/or proteins that associate with it. Thus, the different complement of lipids found in 
the brain versus the liver may result in a σ2 receptor with slightly lower binding affinity. This 
observation contrasts with the behavior of the σ1 receptor which appears to maintain consistent 
binding affinity for ligands in different sub-cellular fractions, soluble extracts, in purified form, 
and in lipid reconstituted purified forms [27, 28, 57, 60]. With regard to the effect of a ~3.5-fold 
higher concentration of σ2 receptors in samples prepared with liver membranes (0.04 mg x 9000 
fmol/mg in 0.25 ml = 1440 fmol/ml) versus those made with brain membranes (0.4 mg x 500 
fmol/mg in 0.5 ml = 400 fmol/ml), a higher receptor concentration alone would be expected to 
underestimate ligand affinity [61], where in this case an increased affinity was observed. The 
observed differences in binding affinities could still be the result of factors unassociated with 
receptor specific binding but the data from liver samples processed with both Brandel and 96-
well filtration (which gave nearly identical results) suggests this is not due to the filtration format 
per se. 
 
As mentioned previously several factors contributed to our choice to use rat liver for all sigma 
receptor binding assays performed using the 96-well method. In addition to the historically 
demonstrated equivalence of brain and liver for σ1 binding [28-30], and the almost universal use 
of rat liver for σ2 determinations, the use of liver membranes has additional advantages, 
including: 1) the small amount of membrane required to generate adequate signal reduces the 
likelihood for clogging of filters, 2) the use of one tissue for determination of both sigma 
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receptor subtypes allows a comparison of σ1 versus σ2 binding in a similar molecular 
environment where use of different tissues for determinations introduces some ambiguity in this 
measurement, and 3) one batch of liver membrane is adequate for assaying thousands of data 
points instead of hundreds per batch (~50-100 g tissue/batch) for typical membrane preparation 
scales of rat or guinea-pig brains, facilitating added inter-assay consistency. 
 
Many well characterized membrane bound receptors have been cloned and overexpressed in 
cultured cells for use in binding and functional assays. While the use of cultured cells as a source 
of membranes for sigma receptor binding has been reported their use is not widespread [62, 63]. 
Lee et al. [63] cloned human σ1 into MCF7 cells and produced a cell line with Bmax σ1 = 109 ± 
24 pmol/mg. Membranes from this cell line were used to analyze a series of 32 compounds, 
including several of the reference compounds tested in this study. The Ki values determined for 
(+)-pentazocine, haloperidol, BD1063, and (+)-SKF10,047, and fluvoxamine in their study  [63] 
were similar to the values obtained in this study, suggesting that their system is valid for 
assessing σ1 binding. A similar strategy for σ2 is not possible at this time because this protein 
has not been cloned. However, Schepmann et al. [62] recently reported the use of human RT-4 
cells in binding studies; RT-4 cells contain a moderate expression level of σ2 receptors, (Bmax σ2 
= ~2.1 pmol/mg, Bmax σ1 = ~280 fmol/mg). This cell line showed good agreement with binding 
in rat liver P2 membranes for the four reference compounds tested [62] and the cell line is 
commercially available. While these approaches may be valid, until they are tested more 
rigorously or adopted more widely it is difficult to justify making a switch from the more 
established tissue sources of sigma receptors. 
 
The results obtained for the 2(3H)-benzothiazolone series examined in this study suggest the 96-
well filtration method is suitable for application to novel classes of sigma ligands for use in 
structure-binding affinity studies. A more thorough discussion of the implications of the results 
obtained for this series will be detailed by our collaborators at the University of Mississippi in a 
future publication. However, some preliminary conclusions may be drawn including: 1) 
increased chain length for the heterocycle linker arm results in loss of selectivity for the σ1 
subtype, reflecting marginal changes in Ki at σ1 and significant  changes in Ki for σ2, 2) RB74 
was identified as a new σ1-selective compound with a 3-fold higher selectivity for σ1 versus σ2 
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compared to the lead compound, SN56; RB74 had a Ki σ2/Ki σ1 ratio of ~500  in rat liver P2, and 
3) several analogues were identified which retained low nanomolar affinity for σ1 and exhibited 
a more than 50-fold preference for σ1 versus σ2. Further, because dramatic differences in 
subtype binding were observed in this synthetic series, this study provides useful data for the 
continued development of pharmacophore models for both sigma receptor subtypes. It should be 
noted that the results of this study are consistent with previous reports of compounds with similar 
structures where a longer linker arm results in increased affinity at σ2 [39, 40].  
 
Lipophilicity as measured by octanol/water partition coefficients (logD) has been shown to affect 
ligand binding [64-66]. Berardi et al. [66] reported correlations between logD and σ2 binding 
affinities for a series of piperazine and piperidine sigma ligands, where an increase in logD for 
the piperazine compounds resulted in increased affinity, while increased logD for the piperidine 
compounds resulted in a decrease in affinity. To examine the effect of lipophilicity on the 
binding of the 2(3H)-benzothiazolone compounds, logD was calculated and compared to binding 
affinities determined in this study. No correlation between logD and Ki σ2 was noted for the data 
set considered as a whole. When homologous compounds with similar linker chain lengths were 
examined, a significant change in logD resulted in a concomitant significant change in the Ki for 
σ2 only for linker length n=2 and n=3 when the R group was changed from –H to –(CH3)2CH3. 
Therefore, it does not appear that lipophilicity plays a major role in determining the binding 
affinity for the 2(3H)-benzothiazolone compounds examined in this study.  
 
In light of the results obtained in this study caution should be exercised with respect to 
comparisons of σ2 binding data generated from different organ tissues. Researchers often report 
Ki σ2/Ki σ1 selectivity ratios, which due to potential tissue specific differences in binding at σ2 
may be misleading when comparing compounds reported by different groups. In contrast, 
binding at σ1 appears to remain relatively consistent between rat or guinea-pig brain P2 and rat 
liver P2. 
 
The 96-well filtration method presented here has several advantages compared to the 
conventional Brandel filtration based method. In addition to greatly reduced radioactive liquid, 
solid, vial and scintillation waste the 96-well method also eliminates several labor intensive steps 
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and uses less radioligand compared to the Brandel method. Furthermore, because the 96-well 
method uses 1/10 the amount of membrane per sample, a single membrane preparation can be 
used to process much larger numbers of samples, which reduces inter-run variability and time 
spent preparing membranes. Over the course of this study we also observed approximately ½ the 
number of “failed” runs versus the conventional filter method where a high non-specific binding 
signal compromised precise measurements with Brandel filtration. An additional advantage is 
that 96-well plates can be read 2 h after the addition of scintillation cocktail versus 10 h for 
filters from the Brandel; this means 96-well filterplate samples can be run the same day as they 
are processed whereas Brandel samples typically are run the day after processing.     
 
In conclusion, we have demonstrated the suitability of a 96-well method for the analysis of sigma 
receptor binding. This method was validated by assaying reference compounds with the 
traditional Brandel cell harvester with rat brain P2 membranes and compared to results obtained 
with the 96-well filtration method using rat liver P2 membranes. Excellent correlations were 
observed between the two methods for the determination of binding to both σ1 and σ2 subtypes 
despite the use of different assay formats and tissue source for sigma receptors. The excellent 
correlation for binding of reference compounds at σ1 in rat liver P2 versus rat brain P2 suggests 
affinities determined with the new method can be compared to historically reported results 
determined in rat or guinea-pig brain membranes. Additionally, because the method employs the 
same tissue source as is commonly used for σ2 affinity determinations, the results for σ2 binding 
obtained with this method can be compared directly to most reported results for this subtype. The 
validity of the method was further demonstrated by a successful structure-binding affinity 
analysis of a novel series of 2(3H)-benzothiazolone sigma receptor ligands.  
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 Table 1. Binding of [
3
H](+)-pentazocine in rat brain P2 membranes processed by 96-well 
filtration.  
 









0 194 ± 9 208 ± 8 93 
25 876 ± 44 952 ± 131 92 
50 785 ± 127 1029 ± 123 76 




































Figure 1. Binding linearity for σ1 receptors in rat liver P2 membranes labeled with 5 nM 
[
3
H](+)-pentazocine. Non-specific binding (NSB) was determined by the addition of 10 µM 
haloperidol. Data points represent the mean ± SEM of three determinations at each protein 
concentration. The data point at 60 µg total protein corresponds to the point at which the data 
deviates from linearity. 














































Figure 2. Binding linearity for σ2 receptors in rat liver P2 membranes labeled with 5 nM 
[
3
H]DTG with 300 nM (+)-pentazocine. Non-specific binding (NSB) was determined by the 
addition of 10 µM haloperidol. Data points represent the mean ± SEM of three determinations at 
each protein concentration. The data point at 60 µg total protein corresponds to the point at 
which the data deviates from linearity. 
 


























Table 2. Binding affinities of reference ligands at σ1 receptors. 
 
Brain/Brandel Liver/96-well
(+)-pentazocine 6.7 ± 1.2
a 8.65 ± 0.4 13.3 ± 1.8
(-)-pentazocine 44.0 ± 1.2
a 57.2 ± 1.9 47.6 ± 3.8
(+)-SKF10,047 28.7 ± 2.8
a 287 ± 36 288 ± 24
DTG 74.3 ± 13.9
a 57.4 ± 3.3 55.9 ± 3.9
haloperidol 1.9 ± 0.3
a 3.9 ± 0.5 3.3 ± 0.6
NE100 1.54 ± 0.26
b 2.8 ± 0.5 2.0 ± 0.5
BD1063 9.15 ± 1.28
c 15.0 ± 2.1 33.4 ± 4.1
AC927 30 ± 2
d 61.2 ± 5.6 74.3 ± 2.1
fluvoxamine 36
e 64.0 ± 5.2 74.3 ± 9.4
progesterone 338 ± 8
f 234 ± 4.4 99.7 ± 3.1
dextromethorphan 652 ± 33
g 403 ± 22 214 ± 15
rimcazole 867 ± 185
g 2565 ± 36 594 ± 61
SN56 0.56
h 1.7 ± 0.1 1.6 ± 0.1
Compound





NR = not reported. 
aBowen, 1993. Rat brain P2 with 5 nM [3H](+)-pentazocine for σ1 and 3 nM [3H]DTG with 1 µM dextrallorphan for σ2. 
bChaki, 1994. Guinea-pig brain. Note: reported value is IC50. 
cMatsumoto, 1995. Guinea-pig brain P2 with 3 nM [3H](+)-pentazocine for σ1. Rat liver P2 with 3 nM [3H]DTG with 1 µM dextrallorphan 
for σ2. 
dMatsumoto, 2008. Rat brain P2 with 3 nM [3H](+)-pentazocine for σ1 and 3 nM [3H]DTG with 300 nM (+)-pentazocine for σ2. 
eNarita, 1996. Rat brain P1/P2 with 5 nM [3H](+)-pentazocine for σ1 and 5 nM [3H]DTG with 1 µM (+)-pentazocine for σ2. 
fHanner, 1996. Guinea-pig brain P3 with 0.3-0.5 nM [3H](+)-pentazocine. 
gKlouz, 2002. Rat brain P2/P3, described as “synaptosomal” with 2-3 nM [3H](+)-pentazocine. 
hYous, 2005. Guinea-pig brain P2 with 3 nM [3H](+)-pentazocine for σ1 and 3 nM [3H]DTG with 100 nM (+)-normetazocine for σ2. 
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Table 3. Binding affinities of reference ligands at σ2 receptors. 
 
Brain/Brandel Liver/96-well
(+)-pentazocine 1361 ± 134
a 1414 ± 207 1067 ± 94
(-)-pentazocine 108 ± 6
a 108 ± 4.4 58.1 ± 4.0
(+)-SKF10,047 33,654 ± 9,409
a ND >10,000
DTG 61.2 ± 13.4
a 43.3 ± 0.6 24.0 ± 2.3
haloperidol 79.8 ± 20.6
a 155 ± 2 57.2 ± 2.4
NE100 84.6 ± 32.9
b 95.5 ± 1.0 36.2 ± 1.1
BD1063 449 ± 11
c 928 ± 40 462 ± 10.4
AC927 138 ± 18
d 384 ± 34 94.3 ± 3.1
fluvoxamine 8439
e  4818 ± 204 2254 ± 206
progesterone NR >10,000 >10,000
dextromethorphan NR >10,000 >10,000
rimcazole NR  1568 ± 154 719 ± 72
SN56 >1000
h 627 ± 115 248 ± 15





NR = not reported. 
aBowen, 1993. Rat brain P2 with 5 nM [3H](+)-pentazocine for σ1 and 3 nM [3H]DTG with 1 µM dextrallorphan for σ2. 
bChaki, 1994. Guinea-pig brain. Note: reported value is IC50. 
cMatsumoto, 1995. Guinea-pig brain P2 with 3 nM [3H](+)-pentazocine for σ1. Rat liver P2 with 3 nM [3H]DTG with 1 µM dextrallorphan 
for σ2. 
dMatsumoto, 2008. Rat brain P2 with 3 nM [3H](+)-pentazocine for σ1 and 3 nM [3H]DTG with 300 nM (+)-pentazocine for σ2. 
eNarita, 1996. Rat brain P1/P2 with 5 nM [3H](+)-pentazocine for σ1 and 5 nM [3H]DTG with 1 µM (+)-pentazocine for σ2. 
fHanner, 1996. Guinea-pig brain P3 with 0.3-0.5 nM [3H](+)-pentazocine. 
gKlouz, 2002. Rat brain P2/P3, described as “synaptosomal” with 2-3 nM [3H](+)-pentazocine. 





























Figure 3. Correlation plots for binding of sigma reference ligands to σ1 receptors in (A) rat liver P2 
versus rat brain P2 membranes, and (B) rat brain P2 versus literature values determined in rat or guinea-
pig brain membranes. Plots show least squares regression line. Correlation plots yielded Pearson r values 
= 0.97 and 0.95 for plot A and B, respectively. [1, SN56; 2, NE100; 3, haloperidol; 4, (+)-pentazocine; 5, 
BD1063; 6, (-)-pentazocine; 7, DTG; 8, AC927; 9, fluvoxamine; 10, progesterone; 11, (+)-SKF10,047; 
12, dextromethorphan; 13, rimcazole]. 



































































































Figure 4. Correlation plots for binding of sigma reference ligands to σ2 receptors in (A) rat liver P2 
versus rat brain P2 membranes, (B) rat brain P2 versus literature values determined in rat or guinea-pig 
brain membranes. Plots show least squares regression line. Correlation plots yielded Pearson r values = 
0.98, and 0.95 for plot A and B respectively. [1, DTG; 2, NE100; 3, (-)-pentazocine; 4, haloperidol; 5, 
AC927; 6, SN56; 7, BD1063; 8, (+)-pentazocine; 9, rimcazole 10, fluvoxamine]. 




































































Table 4. Binding affinities for 2(3H)-benzothiazolone compounds for sigma receptors in rat liver 




RB65 1 0 578 ± 41 8264 ± 500 14
RB67 1 3 9.7 ± 0.6 716 ± 30 74
RB2 2 2 4.1 ± 0.3 177 ± 26 43
RB4 3 2 3.2 ± 0.02 101 ± 14 31
RB6 4 2 7.0 ± 0.3 2.5 ± 0.3 0.4
RB8 5 2 7.5 ± 0.6 2.4 ± 0.4 0.3
SN56 1 2 1.6 ± 0.1 270 ± 4.7 168
RB10 2 2 1.4 ± 0.1 17.2 ± 1.0 13
RB14 3 2 6.1 ± 1.2 4.3 ± 0.3 0.7
RB16 4 2 4.6 ± 0.4 1.6 ± 0.1 0.3
RB18 5 2 6.3 ± 0.9 2.3 ± 0.2 0.4
RB20 2 2 2.2 ± 0.4 15.3 ± 0.9 7
RB34 3 2 1.9 ± 0.2 4.4 ± 0.3 2.4
RB24 5 2 12.0 ± 0.7 4.1 ± 0.6 0.3
RB75 1 0 116 ± 15 4787 ± 101 41
RB74 1 2 4.5 ± 0.2 2181 ± 127 483
RB26 2 2 3.7 ± 0.3 305 ± 7.0 83
RB28 3 2 10.3 ± 0.9 30.3 ± 2.0 3.0
RB30 4 2 12.2 ± 1.1 8.3 ± 0.8 0.7
RB32 5 2 10.4 ± 0.1 1.1 ± 0.1 0.1
RB36 2 2 2.6 ± 0.4 104 ± 1.9 39
RB38 3 2 4.8 ± 0.1 21.6 ± 4.2 5
RB40 4 2 16.3 ± 0.6 5.7 ± 0.5 0.4









































Table 5. Lipophilicity expressed as logD calculated at pH 8 for 2(3H)-benzothiazolone 
compounds.  
 
RB65 1 0 8264 0.93
RB67 1 3 716 2.92
RB2 2 2 177 1.52
RB4 3 2 101 1.47
RB6 4 2 2.5 1.63
RB8 5 2 2.4 1.92
SN56 1 2 270 3.34
RB10 2 2 17.2 2.82
RB14 3 2 4.3 2.6
RB16 4 2 1.6 2.64
RB18 5 2 2.3 2.96
RB20 2 2 15.3 3.14
RB34 3 2 4.4 2.94
RB24 5 2 4.1 3.43
RB75 1 0 4787 1.36
RB74 1 2 2181 2.8
RB26 2 2 305 2.23
RB28 3 2 30.3 2.16
RB30 4 2 8.3 1.7
RB32 5 2 1.1 2.37
RB36 2 2 104 2.72
RB38 3 2 21.6 2.25
RB40 4 2 5.7 2.47







































Figure 6. Binding affinity at σ2 receptor (Ki σ2) versus lipophilicity (logD) calculated at pH=8 
for homologous 2(3H)-benzothiazolone compounds. The n in the legend denotes the linker chain 
length. (A) A; R= -H, B; R= -CH2CH3, C; R= -(CH2)2CH3. (B) D; R= -OCH2CH3, E; R= -
O(CH2)2CH3.  
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A scintillation proximity assay (SPA) for radioligand 






Sigma ligands exhibit activity in numerous in vivo and in vitro model systems. In vivo, sigma 
antagonists can mitigate the toxic and behavioral effects of psychostimulants, while agonists 
show efficacy in rodent models of depression. Accordingly, sigma receptors represent a 
promising target for therapeutic development. Because there are no established in vitro 
functional assays available for routine screening of sigma ligands binding assays are of increased 
importance. The conventional cell harvester based filtration method used for radioligand binding 
studies with sigma receptors is a low throughput method. 96-well filtration has been 
demonstrated to be an improvement over conventional filtration but the scintillation proximity 
assay (SPA) offers the potential to further increase throughput and improve accuracy and 
precision due to its homogenous nature. In the present work, preliminary data was generated with 
SPA, using conventional sigma radioligands in conjunction with rat liver P2 membranes. The 
studies show that SPA PVT WGA (polyvinyltoluene, wheat germ agglutinin) beads can be used 
for the analysis of ligand binding at both σ1 and σ2 receptors. Competition assays with a limited 
number of reference ligands showed good agreement with results obtained using 96-well 
filtration for both receptor subtypes. Non-specific binding for σ1 receptors labeled with [
3
H](+)-
pentazocine was approximately 40%. Assays for σ2 receptors had an effective non-specific 
binding signal of 60% due in part to the necessity of blocking σ1 binding, which accounts for 
approximately one half of the total specific binding of [
3
H]DTG. The results demonstrate that 
SPA technologies represent a feasible alternative to currently used filtration based methods for 
the determination of sigma ligand binding affinities. However, additional studies will be 
necessary to formally validate this method, and a subtype specific radioligand for σ2 receptors 
may be required to reliably assess σ2 binding using SPA. 
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4.2 Introduction   
 
Radioligand binding continues to serve as a primary screen for new sigma receptor ligands 
because there are no medium or high throughput in vitro assays for sigma receptor activity. The 
scintillation proximity assay (SPA) is a relatively new technology that is designed for use in 
enzymatic and radioligand binding assays. SPA utilizes microscopic beads that produce photons 
when radiolabeled molecules are in close proximity to the bead surface. SPA beads for 
radioligand binding assays exploit the interaction of glycosylation sites on cell membranes and 
bead bound wheat germ agglutinin (WGA), or charge interactions between cell membranes and 
bead bound polylysine, that localize membrane-bound receptors close to the bead surface [1-3]. 
The subsequent binding of radioligands to the bead associated membrane-bound receptors gives 
rise to a signal commensurate with the amount of bound radioligand [1-3]. 
 
Conventional filtration-based binding assays are tedious, time consuming, and generate a 
significant amount of radioactive waste. In SPA all the assay components are combined and read 
in a single assay plate, resulting in less than 25 ml of mixed radioactive waste per 96 samples, 
compared to the ~1 l of aqueous radioactive waste and 300-500 ml of mixed scintillation fluid-
radioactive waste that are generated during processing of 96 samples using a conventional 
Brandel cell harvester. In addition to reductions in waste, the reduced number of manipulations 
and the elimination of the filtration step in SPA results in increased accuracy and precision 
relative to filtration assays [1-4]. Additionally, because SPA can also be performed in 384 and 
1536 well plates the method is amenable to use in high throughput screening (HTS) [1, 4-6]. 
 
SPA assays have been reported for a number of classical membrane bound receptors including 
serotonin, acetylcholine, and opioid receptor subtypes [7-9]; application of the SPA technology 
to the analysis of sigma receptor binding has not been reported. Four of the five SPA bead types 
designed for radioligand binding experiments rely on capture of membranes via interactions of 
wheat germ agglutinin (WGA) on the bead surface and N-acetyl-β-D-glucosaminyl residues of 
glycoproteins [1-3]. Because sigma receptors normally reside subcellularly [10] and the P2 
fraction that is typically used for sigma receptor binding experiments consists largely of 
mitochondria and the mitochondrial associated membrane (MAM) [11, 12] it was not known if 
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WGA binding competent moieties were present in this membrane preparation. Therefore, the 
poly-l-lysine bead type was also assessed in these studies. In total five different bead types are 
available for use in radioligand binding studies: PVT WGA, PVT-PEI Type A, PVT-PEI Type 
B, Ysi WGA and Ysi poly-l-lysine. PVT designates that the bead base is composed of 
polyvinyltoluene, while Ysi indicates a base material composed of yitrium silicate. WGA 
designates an untreated bead with a coating of wheat germ agglutinin, while PEI indicates that 
the bead was treated with polyethyleneimine either before (Type A) of after (Type B) coating 
with WGA. 
 
Implementation of this technology using tritiated radioligands requires receptor expression levels 
greater than or equal to 2 pmol/mg in order to generate adequate signal for accurate 
measurements [1-3, 13]. The P2 fraction of rat liver obtained through differential centrifugation 
contains levels of σ1 and σ2 receptors that exceed this requirement [14] and was thus chosen as a 
source of membrane. 
 
To investigate the feasibility of using SPA for competition binding studies of sigma receptor 
ligands, experiments were performed with the established σ1 receptor radioligand, [
3
H](+)-
pentazocine [15] in conjunction with rat liver P2 membranes and each of the five available SPA 
bead types. Preliminary studies were performed to determine basic assay parameters including: 
1) optimum SPA bead type, 2) incubation time, and 3) membrane to bead ratio. Following 
determination of working conditions the assay was applied to the competition binding analysis of 
three reference sigma ligands. A more limited assessment of binding at σ2 receptors was carried 
out using [
3




4.3 Materials and Methods 
 
4.3.1 Reagents and chemicals 
[
3
H](+)-Pentazocine (specific activity = 29 Ci/mmol) and [
3
H]DTG (specific activity = 53.3 
Ci/mmol) were purchased from Perkin Elmer (Boston, MA). (+)-Pentazocine, haloperidol, 1,3-
di-o-tolylguanidine (DTG), sucrose, NaCl, dimethylsulfoxide (DMSO) and 
tris(hydroxymethyl)aminomethane (Tris), were purchased from Sigma-Aldrich (St. Louis, MO).  
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NE100 (4-methoxy-3-(2-phenylethoxy)-N,N-dipropylbenzeneethanamine hydrochloride), 
BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine dihydrochloride), and fluvoxamine 
maleate were from Tocris Bioscience (Ellisville, MO). SN79 (6-acetyl-3-(4-(4-(4-
fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)–one) was obtained from Dr. 
Christopher McCurdy from the University of Mississippi (University, MS). Coomassie Protein 
Assay reagent was purchased from Fisher Scientific (Pittsburgh, PA). Scintillation proximity 
assay (SPA) beads were from GE LifeSciences (Piscataway, NJ). 
 





H]DTG were prepared in 50 mM Tris, pH 8. 
Concentrations of radioligand solutions were calculated based on CPM measurements and 
specific activities as reported by the manufacturer. 
 
4.3.3 Rat liver P2 membrane preparation  
Rat liver P2 homogenates were prepared as described previously and outlined below from frozen 
tissues obtained from Pel-Freeze (Matsumoto et al., 1995). Tissues were homogenized batch-
wise with a Potter-Elvehjem homogenizer (5-10 strokes with motor driven Teflon pestle) in ice-
cold 10 mM Tris-sucrose buffer (0.32 M sucrose in 10 mM Tris, pH 7.4) using 10 ml buffer per 
g of tissue with ~3 g of tissue per batch. Homogenates from multiple batches were combined and 
centrifuged for 10 min at 1,000 x g, at 4 °C. Supernatants were decanted, combined and 
centrifuged for 15 min at 31,000 x g, at 4 °C. To reduce levels of bound endogenous ligand(s) 
the resulting P2 membrane was washed as follows: 1) pellets were re-suspended in 10 mM Tris, 
pH 7.4 using 3 ml buffer per g of wet tissue, 2) the resulting suspension was incubated for 30 
min at 25 °C, 3) following incubation, the suspension was centrifuged for 15 min at 31,000 x g, 
at 4 °C. The resulting pellets were re-suspended in 10 mM Tris, pH 7.4 buffer at a final 
concentration of 1 g starting tissue weight/1.5 ml. Tissue preparations were aliquoted in 1 ml 
portions and stored at -80 °C. The Bradford assay was used to quantitate protein concentration 






4.3.4 General SPA assay considerations 
Assays utilized 50 mM Tris, pH 8 buffer which is the buffer most often cited in the literature for 
the analysis of sigma receptor binding [16]. Assay volumes were 0.2-0.3 ml, depending on the 
experiment. PVT WGA beads gave the best results and were used for most experiments except 
where noted. Non-specific binding was determined with 10 µM haloperidol. Unless otherwise 
noted membranes and radioligand (and test ligand or haloperidol) were incubated for two hours 
at room temperature (RT) prior to the addition of SPA beads; samples were subsequently 
incubated at RT for various time periods prior to taking scintillation readings. Incubations were 
performed without agitation. Typically, single point determinations were made for samples, 
except for total and non-specific binding controls which were prepared in duplicate, or where 
additional replicate samples were prepared as indicated below. All samples were prepared in 0.5 
ml polypropylene tubes and read with the tubes placed in 6 ml scintillation vials on a Beckman 
LS6500 scintillation counter (Brea, CA).   
 
4.3.5 Determination of optimum bead type  
Initial experiments were conducted to determine the bead type with the best performance. For 
each of the five bead types available for radioligand binding, samples were prepared as follows: 
50 µl of 60 nM [
3
H](+)-pentazocine was added to 30 µg of rat liver P2 membrane in 150 µl 
buffer. Samples were vortexed and incubated for 2 h at RT. Following incubation, a 100 µl 
aliquot of bead solution containing 2 mg beads in buffer was added to samples which were then 
vortexed and incubated at RT. Samples were read on the scintillation counter at 2 h and 20 h 
following addition of the SPA beads. For determination of the contribution of “proximity 
effects” to the non-specific binding signal an additional set of samples was prepared that were 
identical to samples prepared for total binding measurements, except membrane was omitted. 
Proximity effects describe signal due to radioligand that is in close enough proximity to excite 
the beads but is not bound to membrane or receptor. 
 
4.3.6 Determination of binding capacity of PVT WGA beads for rat liver P2 membranes  
To determine the optimum amount of rat liver P2 membrane to use with 1 mg of PVT WGA 
beads, samples were prepared as follows: 50 µl of 40 nM [
3
H](+)-pentazocine was added to 
samples containing from 0 to 20 µg (in 2 µg increments) rat liver P2 membrane in 50 µl buffer. 
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Samples were vortexed and incubated for 2 h at RT. Following incubation, a 100 µL aliquot of 
bead solution containing 2 mg beads in buffer was added to samples which were then vortexed 
and incubated at RT. Samples were read at ~10, 15 and 20 h following addition of beads.   
 
4.3.7 Determination of σ2 binding with [
3
H]DTG 
To determine if SPA could be used for the analysis of σ2 binding, samples were prepared with 
the same procedures that were used for σ1 except [
3
H]DTG was used for receptor labeling and 
binding of [
3
H]DTG to σ1 was blocked by the addition of (+)-pentazocine. Samples were 
prepared with 16 µg rat liver P2 membrane with 10 nM [
3
H]DTG, 1 µM (+)-pentazocine and 2 
mg of PVT WGA beads in a final volume of 200 µl of 50 mM Tris, pH 8. Radioligand and 
membrane were pre-incubated for 2 h in 100 µl of 50 mM Tris, pH 8 prior to addition of 2 mg 
SPA beads in 100 µl of 50 mM Tris, pH 8. Samples were read at 1, 7 and 20 h following addition 
of SPA beads. 
 
4.3.8 Competition binding assays   
To test the suitability of the SPA method for use in determining sigma receptor binding affinities, 
DTG, haloperidol, (+)-pentazocine and SN79 were used as reference compounds and were 
assayed using optimized conditions determined from preliminary studies. Stock solutions of test 
ligands were prepared in DMSO or deionized water at 5 or 25 mM. Dilutions of reference 
ligands for competition studies were made with assay buffer (50 mM Tris, pH 8). Samples were 
prepared as described previously containing 1 mg of PVT-WGA beads, 8 µg rat liver P2, and 10 
nM [
3
H](+)-pentazocine for σ1 assays, or 10 nM [
3
H]DTG for σ2 assays, in a final volume of 
200 µl. Samples were pre-incubated for 2 h in 100 µl of 50 mM Tris, pH 8 prior to addition of 1 
mg SPA beads in 100 µl of 50 mM Tris, pH 8. Samples were read 20 h following addition of 
SPA beads. Test compounds were assayed at 11 concentrations varying from 0.001 – 10 µM.   
 
4.3.9 Data analysis 
The competition binding data were analyzed with GraphPad Prism software (San Diego, CA) 
using a one-site nonlinear regression model to determine the concentration of ligand that inhibits 
50% of the specific binding of the radioligand (IC50 value). Ki values were calculated from the 





4.4.1 Determination of optimum bead type 
As shown in Figure 1, of the five bead types available, PVT PEI Type A and PVT WGA beads 
gave the highest total binding with the lowest non-specific binding (NSB) with [
3
H](+)-
pentazocine. Samples were read at 2 and 20 h; specific binding did not change for PVT-PEI 
Type A or Ysi WGA over this time period while specific binding for PVT-PEI Type B, PVT 
WGA and Ysi poly-l-lysine increased 20-30%. At 20 h post bead addition, non-specific binding 
(NSB), as defined by the addition of 10 µM haloperidol, was 40%, 55%, 46%, 42%, and 44% 
respectively for PVT-PEI type A, PVT-PEI type B, PVT WGA, Ysi WGA and Ysi poly-l-lysine 
beads. Signal due to proximity effects, i.e., the amount of signal observed in the absence of 
membrane versus in its presence, with 10 µM haloperidol added to both samples, ranged from 
35% to 50% and was 44% for the PVT WGA beads. 
 
4.4.2 Determination of optimum incubation time 
Over the course of these studies samples were read at various timepoints following the addition 
of SPA beads to samples. For σ1 binding determinations with [
3
H](+)-pentazocine the highest 
level of specific binding occurred around 20 h with no change in signal with incubation up to 25 
h. Interestingly, determinations of σ2 binding with [
3
H]DTG had the highest specific binding 
signal at 1 h, compared to identical samples incubated for 7 or 20 h. Additional time points were 




4.4.3 Determination of binding capacity of PVT WGA beads for rat liver P2 
The binding capacity of the PVT WGA bead was determined by adding varying amounts of 
membrane, labeled with [
3
H](+)-pentazocine, to 1 mg of bead per sample. Figure 2 shows the 
binding function is curvilinear from 0 to 20 µg membrane with a linear increase in non-specific 
binding over this range resulting in a linear region of specific binding from 0-10 µg of added 
tissue per mg of bead in 200 µl of 50 mM Tris, pH 8. In addition to varying receptor 
concentration with a fixed bead amount, we also tested the effect of bead amount with a fixed 
quantity of membrane. With 30 µg of membrane combined with 0.25 to 3 mg of SPA beads the 
specific binding increased linearly but non-specific binding remained constant at approximately 
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35%. Therefore, it does not appear that excess membrane adversely affects background but as 
demonstrated previously it does lead to non-linear binding of radioligand. It also does not appear 
that there is any advantage to using more than 1 mg/well of SPA beads with our current 
procedure. 
 
4.4.4 Determination of σ2 binding with [
3
H]DTG 
To determine if SPA could be used for the analysis of σ2 binding, samples were prepared with 
the same procedures that were used for σ1 binding except [
3
H]DTG was used for labeling sigma 
receptors. Because [
3
H]DTG does not discriminate between σ1 and σ2 receptors, exhibiting 
nearly equal affinity for both subtypes [15], the standard method of blocking σ1 with (+)-
pentazocine was required [15]. Samples prepared with 16 µg rat liver P2 membrane with 20 nM 
[
3
H]DTG and 2 mg of PVT WGA beads resulted in non-specific binding of ~42%. This is 
similar to the level observed with [
3
H](+)-pentazocine. Addition of (+)-pentazocine to block σ1 
results in a signal approximately 50% lower than in its absence. This produced an effective 40% 
specific binding at σ2. These data are shown graphically in Figure 3. Signal due to proximity 
effects for [
3
H]DTG was approximately 50% compared to approximately 45% observed with 
[
3
H](+)-pentazocine analyzed under similar conditions. 
 
4.4.5 Competition binding of established sigma ligands 
Competition binding curves for haloperidol, (+)-pentazocine and DTG binding to σ1 receptors 
were generated with samples containing varying concentrations of the test ligands, 10 nM 
[
3
H](+)-pentazocine, 8 µg membrane and 1 mg PVT WGA beads in 200 µl total volume. The 
binding curves are shown in Figure 4. For haloperidol and (+)-pentazocine, calculated 
equilibrium dissociation constants (Ki) were in excellent agreement with values determined by 
96-well filtration binding using rat liver P2. For haloperidol, Ki (SPA) = 3.4 nM versus Ki (96-
well) = 3.3 ± 0.6, and for (+)-pentazocine, Ki (SPA) = 15.8 nM versus Ki (96-well) = 13.3 ± 1.8. 
The “96-well” values in the preceding comparison are from the 96-well filtration study that is the 
subject of Chapter 3 of this document. Agreement between SPA and 96-well filtration was fair 
with DTG with Ki (SPA) = 228 nM versus Ki (96-well) = 55.9 ± 3.9. A competition binding 
curve for SN79 binding to σ2 was generated with samples containing varying concentrations of 
SN79, 10 nM [
3
H]DTG, 1 µM (+)-pentazocine, 8 µg membrane and 1 mg PVT WGA beads in 
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200 µl total volume. The resulting binding curve is shown in Figure 5. The calculated 
equilibrium dissociation constant was in fair agreement with the value reported in the literature 
(determined in our lab) using a conventional filtration assay with rat brain P2. The value 
determined in this study was Ki (SPA/rat liver) = 23.8 nM versus Ki (conventional/rat brain) = 




The results of this study suggest that SPA is a feasible alternative technology for determining 
competition binding affinities of sigma receptor ligands; the Ki values for reference compounds 
determined with SPA in this study were in good agreement with binding affinities determined by 
conventional filtration methods. However, additional work will be required to improve the 
performance of this method because background levels currently exceed levels recommended by 
the NIH for SPA assays [19]. Efforts to reduce background were not made in these preliminary 
studies; however, improvements may be achieved through: 1) the use of more highly purified 
receptor preparations, 2) the inclusion of buffer additives, and 3) in the case of the analysis of σ2 
receptor binding, the use of a subtype specific radioligand. 
 
The conditions used to determine Ki values for binding to σ1 receptors resulted in a non-specific 
signal of approximately 40% of the total signal. Approximately 70% of this non-specific signal 
can be attributed to membrane binding, with the remainder due to proximity effects. This 
conclusion is based on signal observed in the presence of added membrane versus signal 
observed in the absence of added membrane. Because most of the non-specific signal is due to 
membrane binding this may reflect the quality of the radioligand. [
3
H](+)-Pentazocine and other 
radioligands have in our hands been demonstrated to degrade and a primary indicator is 
increased non-specific binding. The benchmark would be the level of non-specific binding (15-
20%) that was observed for rat liver P2 membrane processed by 96-well filtration, as determined 
in studies detailed in Chapter 3 of this document.  
 
The high background level we observed may be improved by further purification of the receptor 
preparation or the use of different radioligands. The effect of membrane source and radioligand 
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has been tested in defined systems and differences in signal due to non-specific sources can be 
dramatic. Carrick et al. [8] compared [
3
H]LSD binding to membranes and whole cells from CHO 
and Hela cells expressing human 5-HT6 receptors. They found that membranes from CHO gave 
less than 10% specific binding but whole cells yielded >80% specific binding [8]. Similarly, 
Hela membranes gave <30% specific binding while whole cells treated with sodium boride gave 






H]5-HT with the CHO 
membranes and found <30%, <10% and <20% specific binding respectively [8]. These 
experiments show very clearly that the receptor preparation and radioligand can have a 
significant impact on background levels. 
 
The results of our studies show that SPA WGA beads gave the optimum signal to noise with a 
membrane to bead ratio of 8 µg rat liver P2 per mg of SPA bead. The amount of membrane that 
will bind to SPA WGA beads is limited to 10-30 µg membrane/mg of bead [1-3]. Therefore, the 
amount of membrane bound per mg of bead we observed was consistent with expectations. 
Significant improvements in signal to noise or reductions in the amount of SPA bead used per 
well may be realized for σ1 binding assays if a cell line over-expressing σ1 receptors are used as 
a source of membranes. Filter binding assays with MCF-7 cells stably expressing human σ1 
receptors at ~100 pmol/mg (determined with [
3
H](+)-pentazocine) yielded similar binding 
affinities for reference compounds compared to historical values determined in tissues [20]. 
Therefore, with this or a similar cell line over-expressing σ1 receptors, there is the potential for 
binding 20 to 30-fold more receptors for the same mass of membrane, relative to rat liver P2 
membranes that contain σ1 receptors with a Bmax of ~3 pmol/mg. The increased number of bead 
bound receptors would be expected to generate higher specific signal levels for a given amount 
of SPA bead. Cell lines over-expressing σ2 receptors cannot be produced at this time because the 
σ2 receptor has not been cloned; therefore, this strategy cannot be utilized for the analysis of the 
σ2 subtype. 
 
Incubation times of approximately 20 hours were required for a stable SPA signal with σ1 
receptors. Relatively long incubation times are utilized in most published SPA studies [7, 9]. 
Rodgers et al. [7] reported binding of [
3
H]DPN (diprenorphine) to human µ opioid receptors 
expressed in CHO cells with WGA SPA and a total incubation time of 8 h. Hui et al. [9] used 
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WGA beads with HEK293 cells expressing α4β2 nAChR, labeled with [
3
H]cytosine and 
incubated for 12 h. Our experiments suggest σ1 receptor stability is not a problem because 
signals for σ1 binding increased until 20 h and were stable to at least 25 h. It is not clear why the 
signal for σ2 receptors was highest at 1 h versus 7 or 10 h. If stability issues emerge as the assay 
is further optimized, as evidenced by irreproducible results, or derived Ki values for reference 
compounds that are inconsistent with known values, addition of protease inhibitor(s) to assay 
samples may be necessary. Addition of protease inhibitors to receptor preparations for 





H]DTG was successfully utilized to label σ2 receptors in our study. DTG does not discriminate 
between σ1 and σ2 receptors, exhibiting similar affinity for both subtypes, with Ki σ1 = ~74
 
nM 
and Ki σ2 = ~61 nM [16]. Consequently, it was unclear whether [
3
H]DTG would yield adequate 
specific signal with SPA to support use in further studies. The results suggest that adequate 
signal is obtained with [
3
H]DTG but because only 40% of total binding was specific relative to 
σ2 after blocking σ1 receptors this assay is considerably less than optimal. However, the binding 
affinity determined for SN79 was in fair agreement with the value determined by 96-well 
filtration despite the high non-specific signal. A significant improvement may be realized with 
the development and introduction of a higher affinity and/or more selective σ2 radioligand. 
 
In conclusion, it appears that SPA represents a potentially useful format for assaying sigma 
receptor radioligand binding. A major drawback of the method as currently configured is the cost 
of SPA beads which are approximately $1 per mg or $1/well. While in the final analysis, this 
may be cost competitive with conventional filtration assays if one factors in labor and other 
costs; a reduction in the amount of SPA beads required per sample well by a factor of 2 to 4-fold 
would make the method significantly more attractive. This may be possible if radioligands with 
higher specific activity become available (e.g., [
125
I]) or if cell lines over-expressing receptors 
are used as a source of membranes. However, this method in its current form may still prove 
useful in situations where a researcher has access to a scintillation counter, but does not have a 
cell harvester. It should be noted that the studies presented here utilized a standard scintillation 







































Figure 1. Binding of [
3
H](+)-pentazocine to rat liver P2 membranes analyzed with five SPA 
bead types. Samples contained 10 nM [
3
H](+)-pentazocine, 30 µg rat liver P2, and 2 mg SPA 
beads, in a total volume of 300 µl of 50 mM Tris, pH 8 buffer. (A) For the determination of non-
specific (NSB) binding identical samples were prepared containing 10 µM haloperidol. (B) For 
the determination of background due to the interaction of beads with radioligand (No 





















































































































































































Figure 2. Binding linearity of [
3
H](+)-pentazocine to rat liver P2 with PVT WGA SPA beads. 
Samples contained 10 nM [
3
H](+)-pentazocine, varying amounts of rat liver P2, and 1 mg WGA 
SPA beads, in a total volume of 200 µl. Data points represent single determinations. (A) Total 
and non-specific binding (NSB) for 0-20 µg rat liver P2/mg of SPA beads. (B) Total and non-
specific binding for the linear range of binding. 

















































































Figure 3. Binding of [
3
H]DTG to rat liver P2 membranes with PVT WGA SPA beads. Samples 
contained 10 nM [
3
H]DTG, 16 µg  of rat liver P2, and 2 mg WGA SPA beads, in a total volume 
of 200 µl. Data shown is for 1 h time point which resulted in maximum signal versus 7 and 20 h 
readings. Binding due to σ2 and NSB (σ1 block) was determined by adding 1 µM (+)-
pentazocine. Non-specific binding (NSB) was determined by adding 10 µM haloperidol. Data 
















































Figure 4. Competition binding curves for DTG, haloperidol, and (+)-pentazocine versus [
3
H](+)-
pentazocine at σ1. Samples contained 10 nM [
3
H](+)-pentazocine, 8 µg rat liver P2, and 1 mg 
WGA SPA beads, in a total volume of 200 µl. Test ligands were added at 11 concentrations from 
1 pM – 100 µM. Data points represent single determinations.  



















































Figure 5. Competition binding curve for SN79 at σ2 receptors. Samples contained 10 nM 
[
3
H]DTG, 1 µM (+)-pentazocine, 8 µg rat liver P2, and 1 mg WGA SPA beads, in a total volume 
of 200 µl. Test ligands were added at 11 concentrations from 1 pM – 100 µM. Data points 
represent single determinations. 
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Development of an Alphascreen assay for the 




 5.1 Abstract 
 
The σ1 receptor represents an attractive drug development target for a number of therapeutic 
indications including cancer, depression, psychostimulant abuse, and stroke. Functionally, σ1 
receptors appear to operate primarily via protein–protein interactions and have been shown to 
modulate the activity of a variety of ion channels and signaling molecules. Currently there are no 
in vitro functional assays available that are amenable to routine use for the determination of σ1 
ligand activities. The availability of such an assay would greatly aid in the development of σ1 
targeted therapeutics by providing a rational approach to selecting compounds for in vivo 
evaluation and in facilitating design of new synthetic σ1 ligands.  A recently identified protein-
protein interaction between σ1 and binding immunoglobulin protein (BiP) appears to provide a 
relevant target for selectively evaluating the functional activity of σ1 receptor ligands. 
Alphascreen was chosen as a platform for development of an assay that exploits the disruption of 
this interaction as a read-out of σ1 activation. The current studies utilized Alphascreen for 
experiments with purified affinity-tagged σ1 and BiP proteins in a cell free system, and an 
ELISA format was utilized to examine the behavior of σ1/BiP in lysates prepared from cultured 
cells and animal tissues. The Alphascreen experiments were unsuccessful due in part to the 
apparent interaction of σ1-FLAG with the nickel-chelate donor bead that was intended to interact 
specifically with 6XHis-BiP. However, the proposed Alphascreen scheme performed as designed 
with a control peptide that mimicked the intended interactions of the affinity tags with donor and 
acceptor beads, and yielded important information for the design of future schemes. Attempts to 
capture σ1-FLAG by conventional immunoprecipitation with a FLAG affinity resin were 
unsuccessful, despite successful pulldown of a control bacterial alkaline phosphatase FLAG 
fusion protein in this same system. Attempts to capture σ1 from rat liver or CHO cell lysates on 
polystyrene ELISA plates passively coated with σ1 or BiP antibodies were also unsuccessful. 
Despite predominantly negative results this preliminary assessment provided valuable data for 
future studies. This data coupled with a recent report of a simple procedure for isolating 
endogenously expressed σ1/BiP complexes suggest a functional assay for σ1 ligands based on 
Alphascreen remains a viable research goal. Additional work is proposed that addresses the 





The σ1 receptor functions as a chaperone protein and modulates the activities of ion channels [1-
10]. This modulatory role can be affected by well-established ligands that operate in an 
agonist/antagonist relationship with σ1 receptors [2-4, 7, 11, 12]. Importantly, σ1 receptors are 
also known to translocate from the mitochondrial associated membrane (MAM) to the 
endoplasmic reticulum (ER) and plasmalemma in response to agonist ligand stimulation, 
assuming different roles depending on their cellular location [2, 13, 14]. Currently there are no in 
vitro assays available that are amenable to routine use for screening σ1 ligand activities. The 
availability of such a method would facilitate more efficient development of σ1 receptor ligands 
as potential therapeutics. Therefore, we sought to develop an in vitro assay based on the recently 
identified ligand sensitive interaction between σ1 and binding immunoglobulin protein (BiP) [3]. 




, ATP and established sigma agonist 




 and sigma antagonists, and thus 
appears to provide a relevant target for evaluating the functional activity of σ1 receptor ligands 
[3, 15].  
 
In 2007 Hayashi and Su
 
[3] reported that the interaction of σ1 receptors and BiP regulates Ca
2+
 
signaling between the ER and mitochondria via IP3 receptors localized at focal points called the 
MAM. The σ1/BiP complex was observed by Western analysis following immunoprecipitation 
of σ1 or BiP from CHAPS (3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate) 
lysates of wild-type CHO (Chinese hamster ovary) cells, and CHO cells expressing recombinant 
σ1-EYFP (enhanced yellow fluorescent protein) [3]. The dose-dependant sigma receptor agonist 
sensitive behavior of this σ1/BiP complex was demonstrated by co-immunoprecipitation studies 
with crude lysates of cells expressing σ1-EYFP exposed in situ to sigma ligands [3]. Application 
of sigma receptor antagonists in this system prevented the action of agonists but had minimal 
effect when they were administered alone.  
 
Additional studies with a GST (glutathione S-transferase) fusion construct of the ER luminal 
domain of the σ1 receptor (GST-Sig-1R116-223) coupled to sepharose beads provided evidence 
that the interaction of σ1 with BiP is through this domain and can occur in a lipid- and cell-free 
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environment [3]. Using this system, recombinant BiP was precipitated from a simple buffer 
comprised of 50 mM Tris, pH 7.4, 0.5% NP-40, and endogenous BiP was precipitated from 
crude lysates of rat tissue homogenates [3]. Further, the interaction of the construct and 




, similar to the behavior of the σ1-EYFP/BiP 
complex observed in CHAPS cell lysates from CHO cells expressing σ1-EYFP [3]. Because this 
construct does not contain the putative ligand binding site(s) this system would not be expected 
to respond to application of sigma ligands but the effect of application of ligands as a control was 
not reported. Therefore, it is not certain that the interaction observed in this model is identical to 
the sigma ligand sensitive interaction detected in CHO cell lysates. However, the combined 
evidence strongly suggests that the observed interaction is the same in CHO cells and this model. 
Together, these studies provide support for our proposed approach to utilize lysates from liver or 
cultured cells, or recombinant proteins as a source of the σ1/BiP complex for development of a 
functional assay based on exogenous application of sigma ligands.  
 
A number of in vitro and ex vivo systems have been reported which respond to σ1 agonists in a 
predictable manner [16-19]. However, none of these methods is amenable to high throughput 
use. Moreover, these assays rely on measurement of effects downstream of σ1 activation and 
thus do not provide the simplicity or relevancy that an assay based on the interaction σ1 and BiP 
would. The phenytoin-induced modulation of agonist binding at σ1 in guinea-pig brain 
membrane homogenates is an established effect that appears to distinguish σ1 agonists from 
antagonists [20-23]. However, this effect cannot be exploited as a quantitative activity assay and 
the mechanism of the effect is unknown. Cell-based assays that exploit changes in Ca
2+
 levels 
lack the quantitative precision and dynamic range required to adequately capture accurate dose-
response curves, and also represent downstream effects of receptor activation [16]. Quantitative 
cell based assays relying on σ1 agonist induced neurite outgrowth [19, 24] also depend on 
downstream effects and have so far only been demonstrated with a limited number of 
compounds. The ligand sensitive σ1/BiP interaction represents a mechanism that is: 1) of 
relatively low complexity, 2) appears to be the first step in a cascade of σ1 activities as σ1 
translocates in response to ligand stimulation or cellular stress [3, 11], and 3) is amenable to 
examination with well-established immunological based techniques. Therefore, we believe an 
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assay based on the agonist sensitive interaction of σ1 and BiP provides the best approach 
currently available for screening the functional activity of σ1 ligands. 
 
Assay formats that could potentially facilitate measurement of the intact versus the disrupted 
σ1/BiP complex include conventional immunoprecipitation, ELISA, Alphascreen, and Surface 
Plasmon Resonance (SPR). Alphascreen, the proposed assay format for our studies, is 
immunologically based, relying on recognition of native epitopes, or recognition of tagged over-
expressed proteins [25-28]. Alphascreen beads are available with a variety of common 
immunological substrates attached (streptavidin, protein A/G, anti-affinity tag antibodies, etc.), 
providing considerable flexibility in designing assays [27, 28]. Method development is fast, and 
assays, once developed, are easy to perform with only addition and mixing of components 
required prior to reading on a plate reader. Conventional immunoprecipitation and ELISA 
formats are useful for determining the appropriate bead scheme and determining assay conditions 
but ultimately a properly-designed Alphascreen assay can facilitate medium and high throughput 
analysis with considerably less effort than either of these methods. Moreover, Alphascreen is 
more sensitive and has a higher dynamic range than ELISA, allowing for more precise 
determinations of EC50s [25]. SPR may provide an alternative and perhaps superior means of 
quantitating the σ1/BiP interaction; however, at this stage of method development it does not 
provide the flexibility to investigate experimental variables as efficiently as is possible with our 
proposed methods. Indeed, the requirement of determining the best attachment method, 
corresponding SPR chip and instrumental parameters only serves to compound the complexity of 
the primary goals of observing an in vitro interaction of σ1/BiP, and the effect of sigma ligands 
on this interaction. Therefore, until operational parameters are better defined, SPR does not offer 
any obvious advantages over our proposed methods. 
 
To exploit the interaction of σ1 and BiP for the development of an immunologically-based in 
vitro assay numerous factors must be considered which include: sample source, antibodies, assay 
format, sample preparation, and the assay matrix. Potential sources of σ1 and BiP proteins 
include animal tissue or cell culture derived membranes or lysates, where cell culture derived 
samples can be from wild-type cells or cells expressing recombinant proteins with affinity tags. 
Tagged proteins can also be purified from the over-expressed systems and used in a cell free 
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system. Antibodies are available for several native epitopes on both σ1 and BiP. While 
antibodies for affinity tags are highly specific and provide strong interactions, these tags may 
interfere with the σ1/BiP complex. Further, sample preparation and assay matrices must be 
compatible with the chosen assay format and potential involvement of lipids and/or unidentified 
protein partners in the functional σ1/BiP complex must also be considered. 
 
Despite evidence that a σ1/BiP-like complex can exist in cell free conditions [3], it is not known 
if the σ1 ligand sensitive functional activity of the σ1/BiP complex depends on the complex lipid 
environment of the MAM or if unidentified protein partners are involved. A number of studies 
have demonstrated that detergent solubilized tissues yield σ1 complexed with unidentified lipids 
and/or proteins [29-32]. As a general rule solubilization conditions play a significant role in 
determining the composition of  membrane lysates [33]; therefore, specific detergents and 
conditions (e.g. temperature and time) utilized to isolate the σ1/BiP complex may determine 
whether or not lipids or cofactors that could be necessary for functional activity are co-isolated.   
 
Recent studies by Hayashi and Fujimoto [34] rigorously characterized the lipid components of 
MAM and demonstrated that they correspond to the σ1 receptor containing detergent resistant 
microdomains (DRMs) obtained following solubilization with Tx-114 [34]. This series of studies 
also showed that cholesterol and ceramides serve to anchor σ1 at the MAM, and that solubilized 
σ1 preferentially associates with ceramides. Work by Palmer et al. [35] also supports an intimate 
relationship between 1 and cholesterol, where cholesterol binding domains in 1 form part of 
the putative ligand binding site [35].  
 
With regards to the possibility of the involvement of unidentified protein partners or co-
chaperones in the σ1/BiP complex, σ1 has been reported to directly associate with a number of 
proteins including: K
+
 channels [5], IP3 type 3 receptors, ankyrin proteins [3, 4], voltage gated L-
type Ca
2+
 channels [9] and acid-sensing ion channels [36]. In each of these studies co-
precipitation provided evidence of a direct protein-protein interaction with σ1 receptors. Hayashi 
and Su [3] also reported detecting small amounts of unidentified proteins in their 
immunoprecipitations of σ1/BiP from CHO cells but it is not known if these participate in the 
σ1/BiP interaction. Therefore, there is the possibility that additional unidentified protein partners 
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could be involved in the interaction of σ1 and BiP which would dictate that activity assays focus 
on biologically derived proteins as opposed to recombinant proteins. 
 
A very recent study by Ha et al. [15] using RGC-5 cells with a co-immunoprecipitation assay 
similar to that reported by Hayashi and Su [3] showed that the σ1/BiP interaction is observed 
concurrently with phosphorylation of σ1 [15]. The authors assert that the σ1/BiP interaction is 
modulated by phosphorylation of σ1, as evidenced by their observations that: 1) oxidative stress 
increased the level of σ1/BiP complexes and resulted in increased phosphorylation of serine on 
σ1 receptors (Ser117 and/or Ser192), and 2) application of (+)-pentazocine prior to oxidative 
stress returned the amount of complex to baseline levels and prevented serine phosphorylation 
[15]. It is not clear from these studies if formation of the complex requires phosphorylation or if 
phosphorylation occurs as a result of complex formation. This is the first report that regulatory 
control of σ1 receptors may be influenced by its phosphorylation state. If phosphorylation is 
required for a σ1/BiP interaction this has significant implications for development of an in vitro 
assay based on either purified recombinant proteins or cell membrane derived preparations. 
However, Hayashi and Su’s demonstration that the recombinant GST-Sig-1R116-223 construct 
was able to precipitate recombinant BiP or endogenous BiP from crude homogenates of rat 
tissues suggests that a σ1/BiP-like complex can form in simple model systems [3].  
 
In the present study Alphascreen was evaluated with a control peptide and with purified tagged 
recombinant proteins in buffer solutions and with added detergent and/or lipid. Supporting 
studies were performed in an ELISA (enzyme linked immunosorbent assay) format with 
solubilized rat liver and CHO cell lysates. The goal of these efforts was to isolate and detect the 
σ1/BiP complex reported by Hayashi and Su [3] and determine if an immunologically based 
functional assay could be developed that exploited the disruption of this interaction as a read-out 
of σ1 receptor activation by agonist ligands. The goals of these studies were: 1) to determine if 
Alphascreen provided a viable platform for development of a σ1 activity assay, 2) to determine if 
such an assay could be performed with recombinant affinity tagged fusion proteins in buffer or 
simple detergent or lipid solutions, and 3) to determine if solubilized rat liver P2 or CHO cell 




5.3 Materials and Methods 
 
5.3.1 Chemicals and reagents and materials  
[
3
H](+)-Pentazocine (specific activity = 29 Ci/mmol) was purchased from Perkin Elmer (Boston, 
MA). (+)-Pentazocine, 1,3-di-o-tolylguanidine (DTG), and haloperidol were purchased from 
Sigma-Aldrich (St. Louis, MO).  NE100 (4-methoxy-3-(2-phenylethoxy)-N,N-
dipropylbenzeneethanamine hydrochloride) was from Tocris Bioscience (Ellisville, MO). 1 N 
Hydrochloric acid, Microscint-20, Costar Untreated polystyrene plates (9017), Costar High Bind 
polystyrene plates (9018), Costar Easy Wash High Bind polystyrene plates (3369), Costar 
Untreated polyvinylchloride plates (2797), 100X HALT protease inhibitor cocktail and Unifilter-
96 GF/B filter plates were purchased from Fisher Scientific (Pittsburgh, PA). Dulbecco’s 








) was from Invitrogen 
(Carlsbad, CA). Recombinant active human 6X-His BiP (AB78432) was obtained from Abcam 
(Cambridge, MA), and the purified human σ1-myc-FLAG protein (TP301206) was from Origene 
(Rockville, MD). Alphascreen nickel-chelate donor beads and FLAG-Ab acceptor beads were 
from Perkin Elmer (Waltham, MA). Anti-FLAG M2 affinity gel, 3XFLAG peptide, amino-
terminal FLAG-BAP fusion protein, CelLytic M, CHAPS, CaCl2, 
tris(hydroxymethyl)aminomethane (Tris),  fatty acid free bovine serum albumin (BSA), 2,2’-
azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) diazonium salt (ABTS), phosphate-citrate 
buffer, Tris buffered saline with Tween 20, pH 8 (Tris-Tween, T9039) and the 30% hydrogen 
peroxide solution were from Sigma-Aldrich. Mouse anti-human BiP aa525-628 (BD610979) 
antibody was from BD Transduction Lab (Franklin Lakes, NJ). Rabbit anti-human BiP aa24-43 
(AB32618) and rabbit anti-rat σ1 “c-terminal” (AB53852) were from Abcam. A custom chicken 
anti-rat σ1 aa65-78 antibody was purchased from Aves laboratories (Tigard, OR). The mouse-
anti-FLAG M2 antibody (F1804), horse radish peroxidase (HRP) conjugated goat-anti-mouse 
antibody (A9917) and HRP conjugated goat-anti-rabbit antibody (A0545) were from Sigma-
Aldrich. The biotin conjugated rabbit-anti-chicken antibody (G2891) was from Fisher Scientific 
and was used in conjunction with streptactin-HRP from Bio-rad (Hercules, CA). Precision Plus 
Protein Western C molecular weight markers were also from Bio-rad. SuperSignal West Pico 




5.3.2 Test compound solutions 
Stock solutions of (+)-pentazocine, DTG, haloperidol, and NE100 were prepared in DMSO. 
Dilutions for use in preparation of samples were made in assay buffers specific to the assay in 
which they were used. 
 
5.3.3 CHO cell culture 
CHO-K1 cells were obtained from the American Type Culture Collection (Lot number, 
58078551, passage number unknown, ATCC; Rockville, MD). Cells were grown in F-12K 
medium (ATCC) supplemented with 5% heat inactivated fetal bovine serum (Sigma-Aldrich), 
100 units/ml penicillin and 100 µg/ml streptomycin (Sigma-Aldrich). Cells were maintained at 
37ºC in 5% CO2. Passage of cells was performed using 0.25% trypsin/0.5 mM EDTA 
(Invitrogen; Carlsbad, CA).  
 
5.3.4 CHO cell lysates 
CHO cell lysates were prepared in 0.2% CHAPS, 2% CHAPS, or in CelLytic M. For each cell 
lysate, cells from two sub-confluent 175 cm
2




and centrifuged at 500 x g for 5 min at 4 ºC. For lysates prepared in CHAPS, solutions 
containing 2.5 ml of 0.2% or 2% CHAPS in 50 mM Tris, pH 7.4 with 1X HALT were added to 
pelleted cells. For lysates prepared in CelLytic M, a solution of CelLytic M containing 1X 
HALT in a total volume of 2.5 ml was added to pelleted cells. The re-suspended cells were 
rocked for 1 h at 4 ºC followed by centrifugation at 16,000 x g for 15 min at 4 ºC. Supernatents 
were transferred to clean tubes and maintained on ice until use.  
 
5.3.5 Rat liver and Rat brain P2 
Rat liver and rat brain P2 homogenates were prepared from frozen tissues obtained from Pel-
Freeze (Rogers, AR). Tissues were homogenized batch-wise with a Potter-Elvehjem 
homogenizer (5-10 strokes with motor driven Teflon pestle) in ice-cold 10 mM Tris-sucrose 
buffer (0.32 M sucrose in 10 mM Tris, pH 7.4) using 10 ml buffer per g of tissue with ~3 g of 
tissue per batch. Homogenates from multiple batches were combined and centrifuged for 10 min 
at 1,000 x g, at 4 °C. Supernatants were decanted, combined and centrifuged for 15 min at 
31,000 x g, at 4 °C. To reduce levels of bound endogenous ligand(s) the resulting P2 membrane 
 
109 
was washed as follows: 1) pellets were re-suspended in 10 mM Tris, pH 7.4 using 3 ml buffer 
per gram of wet tissue, 2) the resulting suspension was incubated for 30 min at 25 °C, 3) 
following incubation, the suspension was centrifuged for 15 min at 31,000 x g, at 4 °C. The 
resulting pellets were re-suspended in 10 mM Tris, pH 7.4 buffer at a final concentration of 1 g 
starting tissue weight/1.5 ml. Tissue preparations were aliquoted in 1 ml portions and stored at -
80 °C. The Bradford assay was used to quantitate protein concentration [37]. 
 
5.3.6 CHAPS solubilized rat liver and rat brain P2 
Rat liver and rat brain P2 were solubilized in 0.2% CHAPS as follows. A 1 ml aliquot of liver or 
brain P2 containing 10 mg/ml total protein was centrifuged at 500 x g for 5 min. Following 
aspiration of the supernatant, 1 ml of 0.2% CHAPS in 50 mM Tris, pH 7.4 with 1X HALT was 
added to the resulting pellet. The sample was incubated for 60 min with rocking at 4 ºC and 
subsequently centrifuged for 15 min at 31,000 x g, at 4 ºC. The supernatant was transferred to a 
clean polypropylene tube and maintained on ice until use.    
 
5.3.7 Radioligand binding of rat liver P2 versus solubilized rat liver P2 
A standard radioligand binding experiment was performed to compare binding of [
3
H](+)-
pentazocine to “native” and solubilized rat liver P2 samples. To determine total binding, 5 nM 
[
3
H](+)-pentazocine was added to 25 µg (total protein) samples of native and CHAPS solubilized 
rat liver in a total volume of 0.5 ml of 50 mM Tris, pH 8. Samples for the determination of non-
specific binding were prepared by addition of 10 µM haloperidol. Total and non-specific binding 
samples were prepared and processed in parallel. Samples were incubated for 2 h at 25ºC and 
filtered through Perkin Elmer Unifilter GF/B filter plates using a Connectorate 96-well harvester 
(Dietikon, Switzerland). Samples were washed 5 times with 0.2 ml of 10 mM Tris, pH 8 and air 
dried prior to adding scintillation cocktail. Filter plates were soaked in 0.5% polyethyleneimine 
(PEI) for 30 min prior to use to reduce non-specific binding. Processed samples were counted on 
a Perkin Elmer Microbeta2 2450 microplate counter (Waltham, MA), in the Unifilter plate, 






5.3.8 ELISA assays 
A sandwich-type ELISA was utilized to test for capture and detection of the σ1/BiP complex 
present in CHAPS solubilized rat liver and rat brain P2. Four different sample plate types were 
tested, including plates of different base plastic and treated and untreated plates (Costar product 
numbers 2797, 3369, 9017 and 9018). Control samples consisted of adding buffer alone to 
antibody coated wells at the appropriate step of the assay. Rat brain P2 served as a second 
control as it is known to contain approximately 1/6 the number of σ1 receptors per mg of protein 
compared to rat liver P2, so would be expected to generate 1/6 the signal derived from rat liver 
P2. The general assay scheme is shown schematically in Figure 1. Sample plates were coated 
with σ1 antibody (Aves custom), 100 µl/well, containing 1 or 10 µg/ml antibody in carbonate 
buffer, pH 9.6. Plates were incubated overnight at 4 
o
C. All incubations were accompanied by 
gentle agitation on an orbital plate shaker. Following a PBS wash, plates were blocked with 1% 
BSA in carbonate buffer, 200 µl/well. Following incubation for 1 h at room temperature (RT), 
plates were washed with PBS and samples of 0.2% CHAPS solubilized liver or brain P2 
containing 100 µg total protein in 100 µl/well, were added. Control wells were prepared by 
addition 0.2% CHAPS, 100 µl/well. To test for ligand and Ca
2+
 sensitivity, 10 µl of 10X 
solutions of  CaCl2, (+)-pentazocine, NE100, (+)-pentazocine with CaCl2, or NE100 with CaCl2 
were added to samples in wells for final concentrations of 1 mM CaCl2 and/or 1 µM ligand; for 
control samples 10 µl buffer was added. Following incubation for 1 h at RT, plates were washed 
with PBS containing 1 mM CaCl2 (PBS/Ca
2+
) followed by addition of 100 µl of a 1/1000 
dilution of mouse anti-human BiP aa525-628 antibody (BD610979) or rabbit anti-human BiP 
aa24-43 antibody (AB32618). Following incubation for 1 h at RT, plates were washed with 
PBS/Ca
2+
 and 100 µl of a 1/10,000 dilution of HRP conjugated goat-anti-mouse or goat-anti-
rabbit antibody was added. Following incubation for 1 h at RT plates were washed with 
PBS/Ca
2+
 and 100 µl/well ABTS in phosphate-citrate buffer containing hydrogen peroxide was 
added. Following 30-60 min of light agitation, plates were read on a Biotek Multi-plate reader 
(Winooski, VT) at 405 nM. The ABTS solution was prepared by dissolving 1 tablet (Sigma 
P4809) in 100 ml of 0.05 M phosphate-citrate buffer, pH 5.0 and adding 25 μl of fresh 30% 
hydrogen peroxide. To confirm that the ABTS/HRP reaction was patent, 10 or 20 µl aliquots of 




5.3.9 Capture of σ1/BiP complex on antibody coated polystyrene plates 
Antibodies for σ1 and BiP were passively adsorbed to polystyrene plates and tested for capture 
of σ1, BiP or the σ1/BiP complex from CHO cell lysates. Treated polystyrene sample plates 
(Costar 9018) were coated with both available σ1 antibodies (AB53852, Aves custom) and both 
BiP antibodies (BD610979, AB53852) by incubating 100 µl of 2 µg/ml solutions of antibody in 
carbonate buffer, pH 9.6, overnight at 4 ºC. Plates were washed with PBS, blocked with 1% BSA 
in PBS for 1 h, and washed with PBS prior to application of CHO cell lysates. CHO cell lysates, 
100 µl, were incubated in coated wells for 1 h at RT. Following incubation, wells were washed 
with 1 mM CaCl2 in PBS. For PAGE/western blot analysis samples were desorbed from plates 
by addition of 5 µl of 1X Laemmli buffer (125 mM Tris, pH 6.8, 4% sodium dedecyl sulfate, 
20% glycerol and 0.004% bromophenol blue) followed by incubation for 5 min at ambient 
temperature with shaking. Four wells for each sample were prepared and combined for loading 
on gels. Crude lysates were diluted 1:1 with 2X Laemmli and 10 µl was loaded per lane. Prior to 
loading on gels all samples were incubated for 5 min in boiling water.      
 
5.3.10 Alphascreen assays 
 Preliminary studies focused on demonstrating that the proposed assay scheme could detect the 
interaction of purified σ1-FLAG and 6XHis proteins utilizing a nickel chelate donor bead and an 
anti-FLAG coated acceptor bead. The general assay scheme shown in Figure 2A is an adaptation 
of the scheme proposed for detection of σ1-FLAG and endogenous BiP as shown in Figure 2B. 
A control peptide comprised of 6XHis and the FLAG sequence separated by a 12 amino acid 
linker (HHHHHH-GASGSAASGSAG-DYKDDDDK) was utilized to determine starting 
conditions, define expected signal ranges, and to determine if sigma ligands, buffers or other 
additives had an effect on the signal generated by the interaction of the peptide with the 
Alphascreen beads. Following determination of appropriate starting conditions, samples 
containing purified recombinant σ1-FLAG and 6XHiS BiP were prepared to determine if a 
σ1/BiP interaction could be detected, and if the complex was detected, to test its sensitivity to 
Ca
2+
, sigma ligands and EDTA. Samples for all Alphascreen studies were prepared in duplicate 
unless otherwise indicated and were read on an Envision Multilabel Microplate Reader (Perkin 
Elmer, Waltham, MA). All data reported from Alphascreen studies represent the average of 
duplicate determinations for each condition tested. 
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5.3.11 Alphascreen with control peptide 
To establish starting conditions and test the performance of the proposed Alphascreen scheme  
(as illustrated in Figure 2B), preliminary experiments were performed with a control peptide 
comprised of an N-terminal 6XHis tag, and a C-terminal FLAG tag, separated by a 12 amino 
acid linker (HHHHHH-GASGSAASGSAG-DYKDDDDK). Samples were prepared in 1X 
Alphascreen Universal buffer (PBS pH 7.2 with 0.05% BSA, “AU buffer”) and contained 20 
µg/ml Alphascreen donor and acceptor beads (nickel-chelate donor and FLAG-Ab acceptor) and 
varying concentrations of the 6X-His/FLAG control peptide in a total volume of 50 µl/sample. 
To confirm that the signal observed was due to the specific interaction of the control peptide with 
the donor and acceptor beads additional samples were prepared containing 200 nM control 
peptide with 200 nM FLAG peptide or 200 nM 6XHis-BiP as competitors for binding to the 
respective beads. To confirm that the interactions of the tags with their respective beads were 
insensitive to sigma test ligands or added Ca
2+
, additional samples containing 200 nM control 
peptide were prepared containing 10 nM DTG, (+)-pentazocine, haloperidol, NE100, or 1 mM 
CaCl2. 
 
 5.3.12 Alphascreen with purified σ1-FLAG and 6XHis-BiP fusion proteins 
Assays with the purified tagged recombinant proteins were performed using conditions 
determined with the control peptide. Samples contained 20 µg/ml Alphascreen donor and 
acceptor beads, 0.5 mM CaCl2 and 50 nM σ1-FLAG and/or 6XHis-BiP, in AU buffer in a total 
volume of 50 µl/well. Sample components were preincubated for one hour at RT in a volume of 
30 µl prior to the addition of 20 µl of a solution containing 50 µg/ml of both donor and acceptor 
Alphascreen beads in AU buffer. Additional samples were prepared containing EDTA or sigma 
ligands to test their effect on signal levels. Peptide control samples were also prepared containing 
peptide or peptide with added sigma ligand or EDTA. To test the effect of added CHAPS 
detergent or phosphatidylcholine (PC), another set of samples were prepared containing 0.2% 







5.3.13 Capture of σ1-FLAG on FLAG-antibody affinity bead / FLAG pulldown assay 
The purpose of this assay was to test if recombinant σ1-FLAG can function in an 
immunoprecipitation assay similar to the GST fusion protein (GST-Sig-1R116-223) pulldown 
assay described by Hayashi and Su [3]. Samples contained 30 µg anti-FLAG M2 beads, 200 ng 
σ1-FLAG, 500 ng 6XHis-BiP, 200 ng σ1-FLAG + 500 ng 6XHis-BiP or 200 ng of the control 
BAP-FLAG fusion protein in a total volume of 1 ml of binding buffer (0.5% Nonidet P-40, 50 
mM Tris, pH 7.4 and 2 mM Ca
2+
). Samples were incubated overnight with rocking at 4 ºC. 
Beads were washed with three 500 µl aliquots of binding buffer with centrifugation at 8,000 x g 
x 30 sec between washes to facilitate complete removal of wash buffer with a crimped pipet tip. 
Following the final wash beads were eluted with 20 µl of Laemmli buffer with immersion in 
boiling water for 5 min. Non-immunoprecipitated control samples of each protein (and σ1-FLAG 
with 6XHis-BiP) were prepared in Laemmli buffer and boiled as for immunoprecipitated 
samples.  
 
5.3.14 Western blots 
Samples from antibody coated polystyrene plates and the FLAG pulldown assay were separated 
by SDS-PAGE and transferred to PVDF membranes for Western blot analysis. To detect σ1, σ1-
FLAG or BiP, the PVDF membranes were incubated with the respective primary antibodies at 
the indicated dilutions: chicken-anti-rat σ1 (Aves custom, 1:8000), mouse-anti-FLAG M2 
(F1804, 1:1000), mouse-anti-human BiP (BD610979, 1:10,000) or rabbit-anti-human BiP 
(AB32618, 1:10,000). The secondary antibodies, biotin conjugated rabbit-anti-chicken (G2891), 
HRP goat-anti-mouse (A9917), or HRP goat-anti-rabbit (A0545), were used at a 1:50,000 
dilution. Streptactin-HRP was used at a 1:12,500 dilution. Incubations with antibodies were 
typically 1 h at RT with agitation. Washes were performed with Tris-Tween and antibody 
solutions contained 1% dried milk. Proteins were visualized by chemiluminescence with 










5.4.1 Radioligand binding of solubilized rat liver P2 
Rat liver P2 homogenate solubilized in 0.2% CHAPS resulted in an extract with similar binding 
capacity relative to unsolubilized membrane. Figure 3 shows binding results for non-specific and 
total binding for rat liver P2 versus rat liver P2 solubilized in 0.2% CHAPS. This material was 
used for the ELISA-format assays outlined below.   
 
5.4.2 ELISA assays 
Attempts to run ELISA assays with the Aves σ1 antibody passively absorbed to the plate, using 
solubilized rat liver P2 as sample and “end-point” detection, were unsuccessful. Eight trials were 
attempted with varying samples and sample plates including: 1) liver P2 and buffer control, 2) 
both liver P2 and brain P2 samples in addition to buffer control, 3) with or without addition of 
sigma ligands, and 4) with or without CaCl2, in combination with four different sample plates 
(Costar 2797, 3369, 9017 or 9018). For all conditions tested either no difference in signal was 
observed for the different sample combinations within each trial or if differences were observed 
they were not reproducible between trials. 
 
5.4.3 Capture of σ1 or BiP from CHO cell lysates on polystyrene plate coated with σ1 or BiP 
antibodies 
No capture of σ1 or BiP or evidence of capture of a σ1/BiP complex was observed following 
application of CHO cell lysates to polystyrene plates coated with σ1 or BiP antibodies. Figure 4 
shows the Western blot of sample wells eluted with gel loading buffer following application of 
CHO cell lysates to plates containing σ1 antibodies and probed with the Aves σ1 antibody. No 
bands for σ1 were observed for samples eluted from the antibody coated plates. Similarly when 
the gel was re-probed with either BiP antibody no bands were observed corresponding to BiP; 
however, neither of the BiP antibodies produced signals on any of the blots produced over the 
course of these studies. The plates coated with BiP antibodies gave similar results as those coated 
with σ1 antibodies, i.e., no bands were observed for σ1. There were notable differences in the 
profile observed for the lysates prepared with the different solubilization agents, where the 0.2% 
CHAPS sample contained one band corresponding to σ1, and 2% CHAPS and CelLytic M 
 
115 
samples contained an additional unidentified band at ~75 kDa. The band for σ1 was most intense 
for samples prepared with CelLytic M; the unidentified 75 kDa band was also most prominent in 
the CelLytic M lysate sample.  
 
5.4.4 Alphascreen with 6XHis/FLAG control peptide 
The addition of the 6XHis/FLAG control peptide to Alphascreen beads generated signal in a 
concentration-dependant manner as shown in Figure 5. The concentration-response function 
shows a wide dynamic range spanning ~3 nM to ~3 µM added peptide. As shown in Figure 6, 
the signal generated in the presence of 200 nM control peptide was unaffected by the addition of 
any of the sigma ligands tested at a 10 µM concentration, suggesting that sigma ligands have no 
effect on the association of the fusion tags with their respective capture bead or any detrimental 
effect on the signal. Similarly the addition of CaCl2 had no effect on the signal. Because added 
Ca
2+
 is required to facilitate the σ1/BiP interaction it was important that it had little or no effect 
on the signal. Addition of 6XHis-BiP or 3X-FLAG peptide at a concentration equal to the 
concentration of added control peptide (200 nM) reduced the signal substantially as would be 
predicted if signal was produced by the specific interaction of the control peptide tags with their 
respective Alphascreen beads. 
 
5.4.5 Alphascreen with σ1-FLAG and 6XHis-BiP fusion proteins in Alphascreen Universal buffer 
As shown in Table 1, incubation of Alphascreen beads with σ1-FLAG in AU buffer in the 
absence of 6xHis-BiP generated a substantial fluorescent signal. The same level of signal was 
observed in the sample prepared with σ1-FLAG + 6xHis-BiP; this signal was reduced to 
background levels by the addition of EDTA. These results suggest that σ1 interacts with the 
nickel-chelate donor bead directly and that this interaction can be mitigated upon chelation of the 
bead bound nickel by EDTA. Divalent cations are known to allosterically inhibit binding of 
[
3
H](+)-pentazocine to σ1 [38]. However, it is not certain that the current situation is the result of 
σ1 binding to Ni
2+
 chelated to the bead, or is the result of another non-specific interaction, or 
aggregation. The addition of sigma agonist ((+)-pentazocine) or antagonist (NE-100) did not 
appear to have an effect on the Alphascreen signal for samples containing σ1-FLAG + 6xHis-
BiP. No difference was observed in samples containing σ1-FLAG + 6xHis-BiP in the presence 
or absence of CaCl2. The addition of sigma ligands also had no effect on the fluorescent signal 
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generated in the peptide control samples. The exclusion of CaCl2 from the control peptide sample 
had no effect on the signal relative to samples prepared with 0.5 mM CaCl2. The addition of 
EDTA to the peptide control sample reduced the fluorescent signal substantially suggesting the 
signal observed in the absence of EDTA is due to the interaction of the control peptide with the 
chelated Ni
2+
 of the donor beads and with the acceptor beads.  
 
5.4.6 Alphascreen with σ1-FLAG and 6XHis-BiP fusion proteins in CHAPS and/or added 
phosphatidylcholine 
Samples run in the previous experiment were prepared in PBS/CaCl2 buffer. To test if CHAPS or 
added lipid could mitigate the interaction of σ1-FLAG with the donor bead and/or promote the 
specific interaction of σ1-FLAG and 6XHis-BiP fusion proteins, a similar Alphascreen 
experiment was performed as previously described. The overall signal for all samples prepared 
with CHAPS or PC was lower relative to samples prepared in the PBS buffer (Alphascreen 
Universal buffer), but signal due to σ1-FLAG alone relative to σ1-FLAG + 6XHis-BiP was 
similar with all buffer solutions. Interestingly, for samples prepared with 0.2% CHAPS, PC or 
CHAPS/PC, the addition of sigma ligands increased the signal relative to samples containing σ1-
FLAG or σ1-FLAG + 6XHis-BiP alone. Samples prepared in CHAPS/PC gave a similar signal 
for all samples containing either or both of the recombinant proteins in the absence of sigma 
ligands. The signal due to 6XHis-BiP alone in this buffer suggests additional non-specific 
interactions occur in this assay matrix relative to the other matrices tested.  
 
5.4.7 FLAG Pulldown with σ1-FLAG and FLAG affinity matrix 
Pulldown of recombinant σ1-FLAG from a solution of 0.5% Nonidet P-40, 50 mM Tris, pH 7.4 
and 2 mM Ca
2+
 was unsuccessful, but the bacterial alkaline phosphatase-FLAG (BAP-FLAG) 
fusion protein used as a control sample was successfully precipitated in this system. Figure 7 
shows that samples containing σ1-FLAG or σ1-FLAG + His-BiP loaded directly on the gel gave 
a strong signal for σ1-FLAG at ~25 kDa following blotting of the PVDF membrane with the 
anti-FLAG antibody. Similar samples subjected to immunoprecipitation using the same buffer 
used by Hayashi et al. [3] for successful pulldowns of BiP with the GST-fusion system do not 
show bands corresponding to σ1-FLAG. The BAP-FLAG control sample was successfully 
immunoprecipitated in this buffer as evidenced by a strong band at 50 KDa for both the sample 
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The results from these preliminary experiments did not establish that an Alphascreen assay based 
on the interaction of σ1 and BiP would result in a viable system for quantitation of the functional 
activity of σ1 ligands. However, the experiments performed to test this system did provide 
valuable data for future studies. The model Alphascreen scheme originally intended for use with 
CHO cells expressing σ1-FLAG yielded equivocal results with recombinant proteins due to an 
apparent interaction of the σ1-FLAG protein with the Alphascreen nickel-chelate donor bead. 
This interaction may be the result of association of the σ1 receptor with the chelated Ni
2+
. 
Conditions which might be expected to disrupt this interaction, e.g. high Ca
2+
 concentrations, are 
also likely to affect the interaction of the σ1-FLAG protein with BiP to such an extent that the 
agonist sensitive behavior of the σ1/BiP complex would be masked. Tests of the proposed 
Alphascreen scheme with the control peptide produced a dose-dependant signal that was 
unaffected by high concentrations of sigma ligands or added CaCl2, suggesting that under 
appropriate conditions Alphascreen may still be a viable format for a functional assay based on 
the σ1/BiP interaction. Despite the problems encountered, the theoretical basis for the assay 
remains compelling. Recent studies showing successful immunoprecipitation of the σ1/BiP 
complex from crude cell lysates of wild-type RGC-5 cells [15] suggest that the endogenously 
expressed σ1/BiP complex can be isolated with relative ease with the proper combination of 
cells, detergent, and σ1 antibody. This is in contrast to the necessity of isolating MAM to 
observe the complex present in wild-type CHO cells solubilized in CHAPS [3]. Because we were 
unsuccessful in our attempts to isolate MAM, this simplified method for isolating a patent 
σ1/BiP complex from crude cell lysates may hasten future efforts to develop a functional assay 
based on the σ1/BiP interaction.  
 
Our initial intention was to utilize cell lysates from CHO cells expressing σ1-FLAG as input for 
the Alphascreen assay, similar to Hayashi and Su’s original work with CHO cells expressing σ1-
EYFP [3], but attempts to clone the vector were unsuccessful. MAM was also an intended input 
for Alphascreen, and efforts to isolate MAM from rat liver P2 and CHO cells were made, but no 
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bands were observed on Western blots, corresponding to the σ1 receptor, in the isolated 
fractions. Additionally, radioligand binding suggested that the isolates were not materially 
different from the P2 fraction that served as the starting material for MAM isolation; no 
enrichment of binding was observed on a per mass basis compared to the P2 starting material. 
Because efforts to isolate a fraction that could unequivocally be identified as MAM were 
unsuccessful, the experiments with rat liver P2 and CHO cell lysates were performed as 
described below. Recombinant σ1-FLAG became commercially available soon after these 
problems were encountered, enabling studies to assess the basic functionality of Alphascreen 
with purified σ1 and BiP proteins.  
 
ELISA methods were utilized to make a preliminary assessment of the feasibility of capturing σ1 
or the σ1/BiP complex from rat liver P2 with our custom σ1 antibody passively adsorbed to 
ELISA plates. This would support use of endogenously expressed sigma receptors in conjunction 
with our custom σ1 antibody in an Alphascreen assay. Rat liver P2 contains a relatively high 
level of σ1 (~3 pmol/mg); therefore, we believed CHAPS lysates of this material may contain 
sufficient concentrations of σ1 for detection. However, because numerous experiments with the 
CHAPS solubilized rat liver P2 tested in the proposed sandwich ELISA format resulted in 
irreproducible data, a more systematic approach was undertaken where multiple σ1 and BiP 
antibodies were tested for capture of their cognate binding partners from CHO lysates 
irrespective of the σ1/BiP interaction.  
 
Experiments with two different σ1 antibodies, and two different BiP antibodies, passively 
adsorbed to the ELISA plates, failed to effect capture of the σ1 receptor from CHO lysates. 
Failure to capture σ1 with the two σ1 antibodies tested may have been the result of the antibodies 
binding on the plastic surface in an orientation that did not support an interaction with σ1. Use of 
passively adsorbed antibodies is an accepted practice and often yields usable results; however, it 
is highly dependant on the specific antibody and can result in as little as 3-10% of bound 
antibody capable of capturing antigen [39]. Because the total amount of σ1 receptor applied to 
the ELISA plates was ~80 times greater than the amount that was directly loaded and 
successfully visualized on the Western blot, this suggests that if even a small fraction of the σ1 
applied to the plate was captured it should have been detected on the Western blots. It should be 
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noted that our custom polyclonal σ1 antibody targets a different region (residues 65-78) of the rat 
σ1 receptor than the antibodies successfully employed by Hayashi and Su (residues 52-69) [3] 
and Ha et al. (residues 143–165) [15] in their immunoprecipitation experiments. The Abcam σ1 
antibody (ab53852) target sequence is proprietary, but is described as targeting the “C-terminal 
region”; this antibody has been demonstrated to work with Western blotting but has not been 
validated for use with immunoprecipitation. While our custom σ1 antibody has been successfully 
utilized for Western blots, and for flow cytometry with fixed and permeabilized NG-108 cells 
(unpublished data produced in our laboratory), it is not known if it is σ1 binding competent 
under other conditions. The Western blots for BiP have been inconclusive over the course of this 
project; therefore, no conclusion can be made regarding the success or failure to capture BiP. 
 
The Western blots from the above experiments showed that the crude CHO cell lysates prepared 
in CelLytic M or 2% CHAPS yielded a different population of sigma receptors than are produced 
using 0.2% CHAPS. In the CelLytic and 2% CHAPS lysates an additional strong band was 
observed at molecular weight ~75 kDa that may represent a complex of σ1 with lipid or protein. 
This is consistent with reports that different detergents and solubilization conditions result in 
isolation of different molecular complexes of σ1, as determined by gel exclusion 
chromatography [29-32]. This is relevant because it is not known if a functional σ1/BiP complex 
can be isolated using a wide range of solubilization conditions or if one can be isolated at all. In 
light of the report by Ha et al. [15] of immunoprecipitation of a σ1/BiP complex from crude 
lysates of RGC-5 cells, solubilized with a detergent mixture that was substantially different than 
that utilized by Hayashi and Su [3], it appears that successful co-precipitation of a σ1/BiP 
complex can be effected from multiple sources with varied detergents. However, because neither 
group demonstrated the functional activity of the isolated complex with exogenous addition of 
sigma ligands it is not known if either or both isolates contain the necessary components required 
of a functional complex.  
 
Assays with Alphascreen were performed with a control peptide and purified recombinant tagged 
σ1 and BiP (σ1-FLAG and 6XHis-BiP). The results with the model peptide suggested the assay 
worked as designed with the Alphascreen donor and acceptor beads being pulled together via 
their interactions with 6XHis and FLAG sequences flanking a neutral 12 amino acid linker 
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sequence. Studies with the recombinant proteins showed that σ1-FLAG in the absence of 6XHis-
BiP generated a signal of equal intensity compared to when both tagged proteins were added. 
This suggested that σ1-FLAG was interacting with both the FLAG-Ab acceptor bead, and the 
nickel-chelate donor bead. Added detergent or lipid (PC) did not appear to discourage the 
interaction of σ1-FLAG with the nickel chelate bead. It is interesting that the very high 
concentrations of sigma ligands tested in the experiments with neat buffer (without detergent or 
lipid) did not appear to affect this interaction, although this is not certain as ligand was not added 
to a sample containing σ1-FLAG alone; it was only tested in the presence of σ1-FLAG + 6XHis-
BiP. For samples prepared with 0.2% CHAPS, PC or CHAPS/PC, the addition of sigma ligands 
increased the signal relative to samples containing σ1-FLAG or σ1-FLAG + 6XHis-BiP alone. 
This suggests that binding of sigma ligand to σ1-FLAG may have occurred in these samples and 
that this interaction increases the association of σ1-FLAG with the donor bead, increases the 
interaction of σ1-FLAG with 6XHis-BiP, promotes both interactions, or promotes additional 
non-specific interactions of either or both proteins with the beads. Because no samples were 
prepared containing only σ1-FLAG or 6XHis-BiP this cannot be reconciled with the current data. 
It was known that divalent cations can non-competitively inhibit the binding of [
3
H](+)-
pentazocine to guinea-pig cerebellum membranes [38] but it was not anticipated that this would 
result in σ1-FLAG associating with the nickel-chelate donor bead. However, the association may 
be the result of other non-specific interactions unassociated with the bead bound Ni
+2
, but 
because CHAPS or added lipid did not disrupt this interaction, it does not appear to be a result of 
non-specific hydrophobic interactions.  
 
Because of the unanticipated interaction of σ1-FLAG with the nickel chelate bead, a simplified 
system was adopted in an effort to capture σ1-FLAG and/or a σ1-FLAG/6XHis-BiP complex 
with subsequent detection by Western blot. This system mimicked Hayashi and Su’s [3] 
pulldown of recombinant BiP using the GST-Sig-1R116-223 construct. An NP-40 based buffer 
was used as assay buffer in their experiments, suggesting that the σ1/BiP interaction can occur in 
the absence of lipids, similar to the interaction of purified σ1 with ligands [40]. Therefore, to test 
if this buffer would support capture of the σ1-FLAG fusion protein used in our Alphascreen 
assay, and to test if this system could support a detectable σ1/BiP interaction, a conventional 
immunoprecipitation procedure was performed with a FLAG affinity matrix. In this experiment 
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the bacterial alkaline phosphatase-FLAG control was immunoprecipitated but the σ1-FLAG was 
not. Because this material appeared to interact readily with the Alphascreen beads in the PBS, 
CHAPS and phosphatidylcholine buffers, this result suggests that σ1-FLAG may aggregate in 
the NP-40 buffer preventing interaction with the FLAG affinity matrix. Successful Western blot 
detection of the σ1-FLAG control samples loaded directly on the gel, blotted with the FLAG 
antibody, supports this assumption.   
 
Based on the results observed in our studies and more recent work of Hayashi and Fujimoto [34] 
and Ha et al. [15], a number of alternative experiments are proposed. Briefly, the easiest 
experiment to perform would be to acquire a rabbit derived σ1 antibody similar to the one 
prepared by Ha et al. [15], and duplicate their sample preparation and immunoprecipitation 
procedure [15]. Samples would consist of RGC-5 cells exposed in situ to sigma ligands and 
samples prepared by exposing lysates from naïve RGC-5 cells exposed exogenously to sigma 
ligands. This system may very quickly verify or negate the validity of the overall approach and 
provide most of the information necessary to design the appropriate Alphascreen scheme. In the 
absence of an available rabbit derived σ1 antibody our chicken antibody should be biotinylated, 
captured on streptavidin coated magnetic beads, and used in immunoprecipitation with RGC-5 
lysates as described above. A second potential input for the assay which precludes the isolation 
of MAM by Percoll gradient centrifugation involves preparing Tx-114 detergent resistant 
membranes (DRM) from CHO cells using an adaptation of the method described by Hayashi and 
Fujimoto as outlined in Figure 8 [34]. Hayashi and Fujimoto demonstrated that the DRM 
obtained by Tx-114 solubilization of CHO cells is essentially the same material that is isolated 
from P2 using Percoll gradient centrifugation [34] and thus may provide a more reliable method 
for obtaining MAM from CHO cells.  
 
The efforts presented in this study would have benefited from better Western blot 
characterization of the solubilized rat P2 membranes and CHO lysates isolates prior to their use 
in experiments. The inability to produce a usable blot with our BiP antibodies was also a major 
hindrance. The experiment testing the ability to capture σ1 or BiP by passive adsorbtion of 
antibodies on an ELISA sample plate did not inform us if this was the result of a poor antibody 
antigen interaction or if the antibodies were poorly oriented on the plastic surface. As stated 
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previously it would have been preferable to biotinylate our custom σ1 antibody and present it via 
a streptavidin coated plate or bead. Lastly, while some useful information was learned about the 
basic operation of Alphascreen, the experiments were inconclusive with regard to its future use 
in an assay based on the interaction of σ1 and BiP. 
 
Future efforts should emphasize the use of tissue or cultured cell derived, constitutively 
generated, σ1/BiP complex as this alleviates the necessity of extensive molecular biology efforts 
and the possibility that overexpression systems may not faithfully reproduce the functional 
interaction that occurs in vivo or that affinity tags interfere with the σ1/BiP interaction. Similarly, 
a cell free system utilizing purified recombinant affinity tagged proteins would likely require 
significant effort to reconstitute in an artificial lipid environment, which we now know should be 
highly enriched in cholesterol and ceramide. Additionally if phosphorylation of σ1 does indeed 
regulate its interaction with BiP, biological sources of σ1 and BiP may be the only way to 
faithfully recapitulate the endogenous situation in a model system. Because the Alphascreen 
platform can accommodate the use of almost any antibody, the primary limitation that would 
preclude its use would be incompatibility with the detergent solutions utilized to isolate 
functional σ1/BiP complexes identified using immunoprecipitation. 
 
In conclusion, we did not determine if Alphascreen will provide a suitable platform for the 
analysis of σ1 functional activities based on the interaction of σ1 and BiP. The current studies 
also failed to determine if the σ1/BiP interaction can be observed with recombinant affinity 
tagged fusion proteins in buffer or simple detergent or lipid solutions. While the choice of the 
nickel chelate donor bead was unfortunate it is not clear why σ1 interacts with this material with 
such high avidity. The σ1-FLAG protein appears to interact with the FLAG acceptor bead in 
PBS buffer and 0.2% CHAPS (presumably via antigen:antibody interaction) but the FLAG tag 
appears to be unavailable for binding with the anti-FLAG affinity matrix in a simple NP-40 
buffer. Our experiments also did not determine if solubilized rat liver P2 or CHO cells would 
serve as a suitable input for Alphascreen; however, the use of biotinylated or IgG antibodies with 
conventional immunoprecipitation on streptavidin or protein A/G matrices would likely provide 
more definitive answers than the passive adsorbtion of antibodies used in our studies. Use of 
wild-type CHO or rat liver isolates may require extensive experimentation with detergents, or 
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additional purification to yield σ1 enriched material, but may be as simple as isolating Tx-114 
DRM from either receptor source. However, prior to embarking on any additional new 
approaches it is reasonable to propose that the RGC-5 cell/detergent cocktail utilized by Ha et al. 
[15] may provide the simplest means for determining if the σ1/BiP complex in lysates exposed 

























      
 
 
Figure 2. General scheme for detection of interaction of σ1-FLAG with (A) 6XHis-BiP or (B) 
endogenous BiP. 
 


























Figure 3.  Binding of [
3
H](+)-pentazocine to rat liver P2 and P2 solubilized in 0.2% CHAPS. 
Approximately 25 µg total protein was incubated with 5 nM [
3
H](+)-pentazocine in the presence 
(blank) or absence (total) of 10 µM haloperidol. Data are averages of triplicate determinations; 






















































































Figure 4. Western blot following attempt to capture σ1 from CHO cell lysates on antibody 
coated 96-well ELISA plates. Blot was probed with Aves σ1 antibody.  Note that the band at ~75 





























































































Figure 5. Titration of Alphascreen beads with control peptide shows a wide dynamic range, low 
signal to background ratio, and the expected “hooking” effect at high peptide concentrations. 
Samples contained 20 µg/ml donor and acceptor Alphascreen beads and varying concentrations 
of the 6X-His/FLAG control peptide in 1X Alphascreen universal buffer (PBS) in a total volume 








































































Figure 6. Effect of added CaCl2, sigma ligand, or competitor for donor or acceptor beads. 
Purified 3XFLAG peptide and recombinant 6XHis-BiP were capable of reducing signal derived 
from the control peptide, presumably via competitive interaction with the acceptor and donor 
beads respectively. Samples contained 20 µg/ml donor and acceptor Alphascreen beads, 200 nM 
6X-His-FLAG control peptide and the indicated test ligands in 1X Alphascreen universal buffer 
in a total volume of 50 µl/sample. CaCl2 and sigma ligands were at 1 mM and 10 µM final 

































































Table 1. Alphascreen signal produced by recombinant σ1-FLAG and 6XHis-BiP versus control 
peptide. Samples contained 50 nM σ1-FLAG and/or 50 nM 6XHis-BiP, 0.5 mM CaCl2, and 20 
µg/ml donor and acceptor bead in PBS pH 7.2 with 0.05% BSA. Proteins, CaCl2, EDTA and 
ligands were pre-incubated 1 hour prior to bead addition. Samples with added sigma ligand 
contained 100 nM or 10 µM ligand as indicated. Tabulated data are averages of duplicate 












Blank 9096 3714 7932
σ1-FLAG + 6XHis-BiP 63761 8086 23439 20060
σ1-FLAG 56020 7849 24433 22768
6XHis-BiP 12079 4175 13184 18980
σ1 + BiP + (+)-pentazocine 65710 11950 53432 26247
σ1 + BiP + NE100 70443 11813 58370 29503
σ1 + BiP No CaCl2 62477 - - - 
σ1 + BiP + EDTA 25944  -  - - 
Peptide 137698 47358 90100 60506
Peptide + (+)-pentazocine 122370 37220 87748 50884
Peptide + NE100 115377 43999 99429 48921
Peptide No CaCl2 121883 - - -
Peptide + EDTA 31941 - - -
 
1
[Sigma ligand] = 10 µM
2






























Figure 7. FLAG pulldown of σ1-FLAG and BAP-FLAG. Contiguous lanes contain non-
immunoprecipitated controls alongside the indicated immunoprecipitated protein(s). The PVDF 
membrane was blotted with FLAG-Ab. Lane 1 is a blank immunoprecipitate control. Lanes 4 
and 6 show a strong band for σ1-FLAG (~25 kDa) that is absent in immunoprecipitated matching 
samples in lane 5 and 7. The bacterial alkaline phosphatase-FLAG sample in lane 9 shows that 










































































Figure 8. Procedure for preparation of σ1/MAM enriched fractions with Tx-114. Samples are 
lysed in 0.5% Tx-114 buffer followed by centrifugation at 12,000 x g. The resulting supernatant 
is centrifuged at 100,000 x g to pellet σ1/DRM. The resulting pellet is solubilized in 0.2% 
CHAPS buffer. Samples should be analyzed for the presence of σ1 and BiP prior to use in 
immunoprecipitations for the σ1/BiP complex and subsequent testing of the isolated complex for 




0.5% Tx-114, 10 mM Tris 7.4, 
150 mM NaCl, 5 mM EDTA, 
PMSF and aprotinin  
30 m @ 4ºC 
 
Sonicate 10 s x 3 
 
Centrifuge 20 m at 12,000xg 
Centrifuge  supernatent  from 
step 1, containing DRM,  for 60 







insoluble debris DRM containing sigma1R 
DRM from 2) into 0.2% CHAPS, 10 
mM Tris 7.4, 2 h @ 4ºC 
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In conclusion, our studies have resulted in: 1) the characterization of a new σ1 receptor selective 
radioligand, and demonstration of its utility in competition binding studies, 2) the development, 
validation and application of a new 96-well filtration based radioligand binding method for the 
analysis of sigma receptor ligands, and 3) demonstration that scintillation proximity assay (SPA) 
technology is a suitable platform for radioligand binding studies of sigma receptor ligands. 
Efforts to demonstrate that the ligand sensitive interaction of the σ1 receptor with binding 
immunoglobulin protein (BIP) can form the basis of an in vitro functional assay for σ1 receptor 
activity were unsuccessful; however, the studies performed and the presentation of the concept 
may provide useful information for future efforts by other researchers. 
 
Our studies show that [
3
H]SN56 can serve as an alternative to [
3
H](+)-pentazocine in radioligand 
binding assays. [
3
H]SN56 exhibits saturable and reversible binding to a single high affinity site 
in rat brain membranes that corresponds to the site labeled by the selective σ1 receptor 
radioligand [
3
H](+)-pentazocine. Further, because SN56 is a σ1 receptor antagonist, while (+)-
pentazocine is an agonist, future studies with the radiolabeled forms of these ligands may reveal 
information that distinguishes functionally active versus inactive ligands. Therefore, our 
characterization of [
3
H]SN56 demonstrates that this radioligand represents an important new tool 
for sigma receptor research. 
 
The 96-well filtration based competition binding assay presented in this dissertation is a 
significant improvement over the conventional Brandel filtration based method. The 96-well 
method reduces waste and increases throughput dramatically while generating comparable data 
relative to the conventional method. Excellent correlations were observed between the two 
methods for the determination of binding to both σ1 and σ2 subtypes despite the use of different 
assay formats and tissue source for sigma receptors. The validity of the method was further 
demonstrated by a successful structure-binding affinity analysis of a novel series of 2(3H)-
benzothiazolone sigma receptor ligands. The study of this compound series identified several 
new high affinity σ1 selective ligands and generated data which will be useful for the 
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development of pharmacophore models for both sigma receptor subtypes, and consequently 
provides for the rational design of future novel sigma ligands.  
 
Our preliminary assessment of SPA for use in competition binding assays of sigma receptor 
ligands suggests this technology has promise for future use in high throughput screening (HTS). 
Currently there are some issues that need to be resolved before the method is generally 
applicable, which include: a high background signal, very long incubation times, and a relatively 
high per sample cost for SPA beads. These problems may be resolved through the use of more 
highly purified tissue membrane preparations, cells lines overexpressing sigma receptors and/or 
the use of radioligands with higher specific activities. Because this method is amenable to HTS it 
may be desirable to continue further development; this depends largely on the interest of the 
science community in sigma receptor based therapeutics. 
 
Our studies supporting the development of a high throughput in vitro functional assay for σ1 
ligands based on the agonist sensitive interaction between σ1 and BiP were largely unsuccessful. 
However, the need for an in vitro functional assay remains and the rational for targeting this 
interaction is sound. Future efforts should focus on demonstrating that a patent σ1/BiP complex 
can be isolated using conventional immunoprecipitation methods and cell lines where the 
interaction has already been established. This includes wild-type Chinese hamster ovary and 
RGC-5 cells. The isolation of a solubilized functional complex from these cells will likely be 
largely dependant on finding appropriate detergent conditions. Additional efforts to adapt the 
method to higher throughput methods should only be attempted following demonstration that a 
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